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Background
Epidemiologic modeling can play a key role in supporting efforts to reach zero transmission
and zero disability of leprosy. It is an efficient and powerful tool for quantifying transmission
patterns and for predicting future trends in leprosy detection and the potential impact of existing
and novel interventions.1 Transmission dynamics of leprosy are inherently nonlinear. Apart
from host factors, an individual’s risk for developing leprosy is determined by the number of
cases in an area and the infectiousness of cases among their contacts. The number of newly
detected cases is determined by past exposure of the individual toM. leprae. Moreover, leprosy
is known for its long incubation time and delayed diagnosis due to difficulties in diagnosis and
fear of stigma.2,3 As a result, measuring the impact of changes in policy can be difficult because
the impact of current changes may not be seen in the short run. Epidemiologic modeling can
help to identify long-term impact of policy changes and optimal (endgame) strategies.1
At the same time, an investment case should be built to inform (local) policy makers and
other donors on the importance of investing in new tools and strategies aimed for achieving
zero leprosy. As the road to zero leprosy requires extensive use of resources, the decision to
commit to zero leprosy initiatives should be based on a robust analysis of the benefits, risks,
and costs to ensure value formoney—especially in less developed settings.4 To guide this process,
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an eradication investment case (EIC) for leprosy is recommended.5 Such a framework would
provide a systematic inventory of what is needed to achieve zero leprosy along with information
about the challenges, risks, and sustainability of an initiative. An EIC is particularly appropriate
for diseases such as leprosy that have a high socioeconomic burden and for which multiple
interventions exist or are being developed. The EIC framework has been recently tailored to the
context of leprosy by Tiwari and Richardus,6 who outlined the following key domains:
. Disease burden and elimination.
. Current state of the leprosy program and recent technical advances.
. Available and new tools and their scope in interrupting transmission.
. Future requirements during and after transmission interruption.
. Biological and technical feasibility of transmission interruption.
. Socioeconomic burden and public goods obtainable.
. Financing leprosy elimination.
. Health systems and their capacity.
A leprosy EIC would help to determine whether zero leprosy is feasible, the capacity of the
initiative to monitor and evaluate control programs, the most promising interventions for
achieving that goal, and the long-term consequences of the interventions. It also includes an
assessment of the health-system changes required in leprosy-endemic countries.3
In formulating their research agenda, the Subgroup on Epidemiologic Modeling and
Socioeconomic Research of the Global Partnership for Zero Leprosy (GPZL) Research
Agenda Working Group reviewed recent modeling work on leprosy and socioeconomic
research and identified important key questions that support efforts to reach zero leprosy and
contribute to the development of a leprosy EIC.
Current knowledge and key questions
Previous modeling work on leprosy has mainly focused on predicting future leprosy trends
and evaluating the impact of various interventions. A leprosy EIC does not exist yet, but a
recent literature review has identified current knowledge and key information gaps on
constructing a leprosy EIC.6 An overview of the key findings from this systematic review was
published separately3 and is presented in the Box below (Figure 1).
To develop a leprosy EIC, input is mainly required from epidemiologic modeling and
socio-economic research. However, developments in research outlined by other subgroups
of the GPZL Research Agenda Working Group (i.e., Diagnostics, Vaccines, PEP, and
Operational Research) are also crucial.
The key findings and knowledge gaps in the field identified by the Subgroup on
Epidemiologic Modeling and Socioeconomic Research are summarized below.
Epidemiologic modeling
FEASIBILITY OF GLOBAL INTERRUPTION OF LEPROSY TRANSMISSION
Interruption of leprosy transmission is unfeasible within two decades without additional
efforts and new interventions.7,8 A next step would be to provide a realistic time frame upon
GPZL Reports on Research Priorities238
which zero leprosy and zero disability can be reached. This information would also be
relevant when developing a leprosy EIC. As zero leprosy has not been formally defined yet,
modeling studies can assess various definitions, such as achieving zero new (child) cases or
sustained zero new leprosy cases. Moreover, modeling studies could also assess the time
frames for reaching intermediate targets.
 Key questions:
– What would be a realistic time frame to achieve global interruption of transmission?
– How long should programs be continued to achieve zero leprosy?
– How should zero leprosy be defined?
POTENTIAL IMPACT OF NEW STRATEGIES AND TOOLS
Universally, studies have highlighted the need for earlier diagnosis and treatment of leprosy,
preferably in the asymptomatic stage, in order to substantially reduce the new case detection
rate (NCDR).9–11 Innovative ways to prevent leprosy include administering post-exposure
prophylaxis (PEP) to contacts of newly diagnosed leprosy patients and providing earlier
diagnosis through screening with diagnostic tools. Amodeling study on leprosy in Para´ State in
Brazil showed that administering a single dose of rifampicin (SDR) to household contacts, in
addition to current controls, would lower the NCDR by 40%.12 Another study showed that the
use of a diagnostic test to detect subclinical leprosy cases could be a crucial step for interrupting
transmission.9 In high endemic settings, the use of a population survey as a testing strategy with
a diagnostic is preferred over household contact testing. Another strategy to consider is poverty
Panel: Key findings of a systematic review on constructing a leprosy elimination investment case
A 2016 systematic review98 identified a number of factors that
should be considered when developing a case for investing in
the elimination of leprosy. The findings listed below, adapted
from that review, are grouped under eight headings, in
accordance with an internationally recognised guide on
preparing disease eradication investment cases.99
The proportion of newly detected leprosy cases in children
younger than 15 years reflects the degree to which
Mycobacterium leprae transmission is occurring.
Disease burden and elimination
Available and new tools and their scope in interrupting
transmission
Current state of the leprosy programme and recent
technical advances
Health systems and their capacity
Financing leprosy elimination
Socioeconomic burden and public goods obtainable
Biological and technical feasibility of transmission
interruption
Future requirements during and after transmission
interruption
The proportion of patients with grade 2 disability (visible
deformity or damage) reflects the degree to which a health
system is achieving early detection and prompt treatment
of patients.
Many leprosy cases escape detection by health systems.2
Leprosy is one of many neglected tropical diseases
associated with poverty.105
Information about the costs of provision of  leprosy services
is scarce.
Integration of a leprosy programme into the general health
system reduces the level of anti-leprosy stigma in a country.
Community-based rehabilitation is effective in integrated
programmes but is used in few health systems.106,107
The disability-adjusted life-year is not a reliable indicator of
the leprosy disease burden.103,104
Genome-based technology will probably facilitate the
development of leprosy vaccines and diagnostic tests.102 
Linking leprosy elimination efforts with programmes
working on other neglected tropical diseases ensures the
sustainability, efficacy, and financial resilience needed to
reach the WHO leprosy elimination goal.2,25 
Contact tracing followed by administration of
chemoprophylaxis, BCG vaccination, or both is currently the
most promising approach to halting M. leprae transmission.
The M. leprae-specific anti-PGL-I antibody test has limited
applicability, because it is only reliably positive in 
multibacillary cases.101
The new PCR test is capable of detecting the leprosy bacillus
and its resistance to drugs,100but its application is limited.
Tracing contacts of index leprosy patients can detect new
cases more effectively than population-based approaches
but faces operational and ethical challenges.12
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Figure 1.
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reduction.13 In Brazil and Mexico, research is being done on cash transfers in relation with
diseases, including leprosy, with promising results.14,15 Also, integrated strategies can be
explored.16 For example, joint detection of tuberculosis (TB) and leprosy could be considered in
some areas,17 with BCG treatment also effective in patients with leprosy. Another example is
the use of skin camps for several neglected tropical diseases (NTDs).
 Key questions:
– What is the potential long-term impact of available and new tools such as vaccines and
diagnostics and their scope in interrupting transmission?
– Which interventions are most promising?
– Which strategy would yield the highest impact on transmission (both in terms of
reduction in incidence and in time until lower infection levels are reached)?
– How can modeling of the impact of poverty reduction on leprosy best be done?
GEOGRAPHICAL VARIATION AND POPULATION AT RISK
. Geographical variation
Current incidence trends show the geographical variability of leprosy. This is also evident
in the predictions from modeling studies. Regions with lower incidence of leprosy are
predicted to reach the 10 per 100,000 threshold within a few years, whereas those with
higher incidence are predicted, with current interventions, to have only a small chance of
reaching this threshold within 20 years.7 This pattern is true at the national scale (e.g.,
India, Brazil, and Indonesia compared to other affected countries) and at a sub-national
level (e.g., among Brazilian states),7,8 and might be true of smaller spatial scales. Also,
differences in breakdown between multi-bacillary and paucibacillary infections may
impact the infection reservoirs and thus transmission.
 Key questions:
– To what extent does the impact of interventions differ among geographical
regions?
– Should interventions be tailored to specific endemicity levels, and, if so, how?
– In which areas is zero leprosy feasible in a relatively short time span?
– How should zoonotic transmission in the Americas be measured?
. Population at risk
The size of the population at risk for leprosy may determine the size of the problem and
therefore could be used for advocacy, awareness raising, and program-planning activities.
However, the population at risk in the context of leprosy is not defined or estimated yet
because of several challenges in making such an estimate. A modeling study is ongoing to
estimate the number of people needing PEP, as a proxy of the population at risk, in order to
substantially reduce the newly detected cases.
 Key questions:
– How should we define population at risk?
– What is the estimated population at risk?
IMPACT OF OTHER EPIDEMIOLOGICAL RISK FACTORS FOR TRANSMISSION
Geographical variation could be dependent on (as yet) largely understudied risk factors,
including environmental reservoirs and host factors that may predispose an individual to
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multibacillary infection.2 Potential host factors include undernutrition and comorbidities/co-
infections.18 These risk factors could be identified through meta-analyses, accompanied by
observational studies or trials.
 Key questions:
– Which epidemiological risk factors are relevant?
– How do we incorporate these types of risk factors into a model?
END-GAME SCENARIOS
No research has been conducted in this area. Endgame scenarios might already be considered
in several regions in the world that report a very low number of new annual cases. These areas
may serve as a blue print for others when they will reach this point. Using modeling, we can
identify what is needed to achieve zero leprosy and what possible post-zero leprosy scenarios
may look like.
 Key questions:
– What is needed to achieve and sustain zero leprosy?
– What are possible scenarios for a post-zero leprosy era?
TESTING HYPOTHESES
In the past, modeling has been used to explore the likelihood of certain hypotheses in the
absence of empirical evidence. A good example is a study that assessed multiple hypotheses
of susceptibility mechanisms in leprosy (genetic vs. non-genetic).19 Epidemiologic modeling
can be used to assess various hypotheses on issues such as transmission dynamics, migration,
and/or drug resistance. Such studies may overlap with the research agendas prioritized by
other subgroups of the GPZL Research Agenda Working Group and should align with those
agendas.
 Key questions:
– What efforts are needed to assess hypotheses regarding transmission dynamics?
– What is the impact of migration on leprosy trends?
– If drug resistance becomes a problem, how would that affect the course of leprosy
incidence?
Economic research
AVAILABLE TOOLS AND THEIR ECONOMIC FEASIBILITY
Cost effectiveness and cost-benefit analyses are essential for identifying the best possible
leprosy control strategy for a specific country or region. Two cost-effectiveness studies have
been published: one on case detection strategies and one on chemoprophylaxis.20,21
Currently, a modeling study on the cost-effectiveness of PEP taking into account future
benefits is ongoing. To determine if an investment is sound, a cost-benefit analysis comparing
the total expected cost of each option against their total expected benefits is recommended.
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 Key questions:
– What is the cost-effectiveness of current and new tools?
– What are the results from cost-benefit analyses conducted in different settings (health
system contexts)?
SOCIOECONOMIC BURDEN OF LEPROSY
. Disease burden
Estimates on the burden of disease due to leprosy rely on disability weights that
underestimate the actual disadvantages resulting from leprosy. First, there is a need to
identify leprosy-associated disability (social and mental issues are not considered
currently), followed by a re-estimate of disability weights for endemic counties or WHO
regions. The burden in children, including the impact of the disease on school dropout,
lifelong stigma, and mental health, should also be considered.
 Key questions:
– What efforts are needed to estimate disability and assess disability weights of
leprosy?
– What efforts are needed to estimate the burden of morbidity due to leprosy and
other NTDs or other diseases that share cross-cutting issues with leprosy?
. Socioeconomic risk factors of leprosy
Socioeconomic risk factors of leprosy include the length of time in poverty, level of
education, and socioeconomic status of the family; nutritional factors; water, sanitation,
and hygiene factors; housing conditions; and the presence of coinfection(s). Previous and
ongoing studies have focused on several of these risk factors for transmission (related to
hotspots). However, studies to determine the importance of each risk factor are still
needed. This evidence may also contribute to epidemiologic modeling.
 Key questions:
– What are the relevant socioeconomic risk factors of leprosy?
– What is the potential impact of each risk factor?
. Monetizing socioeconomic burden of leprosy and associated illness
The social burden of leprosy is hardly estimated but is important for leprosy prevention
efforts due to high social negative impact. The prevalence of social consequences and
public expenditure on social welfare (directly and indirectly related to leprosy) remain
unknown. Also, an analysis of the likely effect of leprosy on economic productivity at the
household and population levels and on social participation is unknown. Willingness-to-
pay studies are needed to quantify/monetize the impact of social consequences (discrete
choice experiment).
 Key questions:
– What is impact of leprosy on economic productivity?
– What is the impact of leprosy on social participation?
– What is the estimated impact of social consequences due to leprosy?
FINANCIAL AND COST ANALYSIS OF LEPROSY AND ASSOCIATED ILLNESS
. Cost analysis of leprosy and associated illness
A study has been published estimating the out-of-pocket expenditures for leprosy
households.21 Direct and indirect household expenditure on leprosy was estimated to be on
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average $5·40–$6·50 and $8·70–$12, respectively. More such studies are needed from
various countries to estimate the total societal cost of leprosy care.
 Key question:
– What is the out-of-pocket expenditure on leprosy for affected households and
individuals in different settings?
. Financial analysis of (global) leprosy programs
The 2015 WHO report on investing to overcome the global impact of NTDs estimated that
the investment in leprosy services would be on average $37 million annually.22 This
includes costs for contact tracing, treatment, and care. It is important for health systems to
facilitate sustained leprosy control activities. However, with low numbers of leprosy cases,
this may become difficult due to financial and human resource constraints and diminishing
ability to diagnose leprosy. A recent study has also assessed the leprosy costs in two
primary health settings in India.23
 Key questions:
– What efforts are needed to develop a systematic method to estimate gross
expenditure per country?
– What is the gross total expenditure on leprosy per country/region?
Subgroup on Digital Health
Lead authors:
David Heard & Fareed Mizra
Novartis Foundation, Basel, Switzerland
Summary
The use of digital health-based interventions in leprosy is limited. Several examples have
been compiled and outlined in this report. There are clearly many opportunities to apply
digital interventions in the broader field of neglected tropical diseases (NTDs). Examples
include digital diagnostics, surveillance, disease mapping, eLearning, policy and digital
strategy, and monitoring and evaluation.
. Leprosy often goes undetected due to a lack of diagnostic tools, awareness of the disease,
or effective screening methods.
. Low-income communities need better access to quality healthcare.
. Digital innovations are being made in the NTD and NCD fields through physician aids,
eLearning and mapping.
National leprosy programs are showing willingness and taking action to incorporate
national digital registries into their prevention efforts. These registries will help ensure
accurate case detection and rates and improve targeting of resources.
Partnerships with the IT sectors could encourage and fuel innovation and funding for
leprosy prevention. The use of digital diagnostics will lead to new research to enable more
rapid diagnosis of disease. These advances will contribute to policy developments and help
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build strategic partnerships for adoption and scale up of new and existing interventions,
which can potentially serve as important models for other NTDs.
The Subgroup on Digital Health of the Global Partnership for Zero Leprosy (GPZL)
Research Agenda Working Group identified several major gaps for digital health application
for leprosy. These include lack of:
. Sufficient evaluations of digital health interventions.
. Interest in and use of digital technologies in the field of leprosy.
. Skilled workers and resources for digital health training and application.
. Scalable and sustainable digital health solutions that can be integrated into national health
systems.
. Strategic planning for successful interventions to be scaled (and applied) to other NTDs.
The Subgroup identified the following digital health research priorities to fill these knowledge
gaps and help reach zero leprosy:
. Geolocalization of cases.
. Digital diagnostics.
. eLearning and hands-on training (with accreditation).
. Policy research, implementation, and tracking.
. Independent evaluation of digital interventions (with scale-up plans).
Existing digital interventions in leprosy
NIKUSHTH FOR PATIENT REGISTRATION
In India, the National Leprosy Eradication Programme (NLEP) has commissioned a digital
tool, called Nikushth, for registration of leprosy patients. This application was built by HISP
India on the DHIS2 platform from the University of Oslo, and is open source.
LEPROSY ALERT RESPONSE NETWORK AND SURVEILLANCE SYSTEM (LEARNS)
The Novartis Foundation and the Department of Health and Department of Science and
Technology in the Philippines have worked together to build an enhanced leprosy referral and
surveillance network among healthcare providers (HCPs). The goal of this project is to have a
positive impact on the disease burden for leprosy in the Philippines by introducing a role-
based tele-dermatology system that will enable health workers to consult with specialists by
providing images of skin lesions and patient details and then get an expert diagnosis for the
patient. The patient can then be referred through the system for further treatment and follow-
up. The system allows for the storage of images and patient details, creation of alerts based on
delayed response by HCPs, unusual case reporting (low or high) in a given region, failure of
follow-up, and other capacities. The system also allows reports to be generated for evaluation
of the regional health centers, system effectiveness, and other considerations. Importantly,
the LEARNS tool has been evaluated for sensitivity and specificity in the clinic and in a ‘real
world’ field setting.
Results of the evaluation have shown that when LEARNS is used new case detection rates
increase while the time to diagnosis decreases (from approximately 2 months to 2·5 days;
Figure 2).
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GIS MAPPING APPLICATION
The Novartis Foundation has also worked with the University of Oslo and HISP India to
develop a GIS mapping application that uses data from Nikushth to provide a visualization of
cases over time at the level of the Indian “block,” an area that includes approximately 50 000
people.
This is currently the most granular level of mapping available; while the name of the
center where the patient was diagnosed is captured in the data, the location of each center has
not yet been given map coordinates. This information will be available soon, however, and
will enable the government to map cases to the location of the health centers and therefore
provide targeted assistance for health worker education, medication provision, and resource
mobilization to strengthen efforts to interrupt transmission. This application is also built with
Figure 3. Capturing an image for the Leprosy Intelligent Image Atlas at Fiocruz in Brazil.
The power of a multi-stakeholder partnership: leveraging
synergistic expertise to address a complex challenge
Challenge 1: Geographic isolation and limited access to health services
Challenge 2: ICT underutilized in devolved health system
Challenge 3: Gaps in program implementation and M&E; low number of leprosy specia
Healthcare worker
sends
message
Coverage : 17 provinces in 5 regions /
33health units / 6,00 HCW trained
Rural physician and
leprosy specialist are
notified
Leprosy specialist
replies
with a diagnosis
Patient consults with
rural physician within two
weeks. Treatment given.
Reports generated.
Figure 2. The LEARNS project in the Philippines.
GPZL Reports on Research Priorities 245
the open-source DHIS2 platform and is therefore available in any country where a digital
patient registration system is in operation.
DIGITAL DIAGNOSTICS
The Novartis Foundation and Microsoft are partnering to develop a proof-of-concept artificial
intelligence (AI)-enabled digital health tool and a Leprosy Intelligent Image Atlas to aid in
the early detection of leprosy. As part of the collaboration, Microsoft and the Novartis
Foundation will work with local investigators from Oswaldo Cruz Foundation (Fiocruz) in
Brazil to develop a protocol to examine anonymized images collected by Fiocruz. This will
include a high-resolution image and metadata capture protocol to process the leprosy skin
lesion images. The imagery and AI code will be publicly accessible at a later stage (Figure 3).
THE SKINAPP
Developed by Netherlands Leprosy Relief (NLR), the SkinApp is a smartphone app
designed to support peripheral health workers in diagnosing and treating common, NTD-
and HIV-related skin diseases. Although skin diseases are highly prevalent, the availability
of dermatologists in many areas is limited (in Mozambique, there are 10 dermatologists
for a population of 27 million people). Many public health centers are run by clinical
officers or nurses who have very limited training in dermatology. NLR developed the
SkinApp after field-testing an adapted version of Mahe´’s algorithm for diagnosis and
treatment of common skin diseases in Nigeria. A first version of the app was field tested in
Zambezia Province in Mozambique, in both urban and rural districts. Findings and
feedback have led to an improved version of the SkinApp that can now be downloaded
and in the Google Play Store. In April, NLR will field test this improved version of the
SkinApp in Mozambique with the aim of improving the quality of diagnosis and treatment
of skin diseases and enhancing early detection of skin-related NTDs as well as HIV-
related skin diseases (Figure 4).
Disclaimer How to use the app Search
Signs & symptoms
Diagnoses
How to manage
Locations
Responsibility of NLR and
SkinApp user
Explanation on how to use the
app
Elaboration on signs &
symptoms and diagnoses
List to select signs &
symptoms for diagnoses
Glossary
Elaboration on signs &
symptoms
Further reading
Extra information on
diagnoses and treatment
options
Body map to select affected
body areas for diagnoses
Diagnoses, treatment options
and next steps for skin
diseases
Information on how to the
manage the broken/dry skin
Figure 4. The NLR SkinApp - home screen.
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BENEFITS OF SKINAPP
. A simple tool to diagnose skin diseases by check-boxes of signs and symptoms and
affected body areas.
. An easy-to-use database of skin diseases, including signs and symptoms, pictures, and
treatment options, which helps in making diagnoses and provides eLearning for
community health workers.
. Available in rural settings since it can be used offline.
DIGITAL HEALTH POLICY
Despite the widespread use of mobile phones (with approximately 99·7% market
penetration), the use of digital health-assisted interventions is uncoordinated and often
fragmented. These interventions and applications rarely reach scale. The Broadband
Commission Working Group on Digital Health has convened the world’s top experts to
develop recommendations on ways that policymakers and other stakeholders can develop
sustainable digital health solutions to address national health priorities. This will help to
accelerate universal health coverage and the achievement of the United Nations’ Sustainable
Development Goal 3.
The Working Group’s 2017 report, Digital Health: A Call for Government Leadership
and Cooperation between ICT and Health, created a blueprint for how information and
communications technology (ICT) and health leaders and policymakers can collaborate to
develop national digital health strategies.
The Working Group’s 2018 report, The Promise of Digital Health: Addressing Non-
communicable Diseases to Accelerate Universal Health Coverage in LMICs, builds on the
earlier work. It provides practical recommendations and best practice examples of how
policymakers can implement sustainable digital health solutions that address NCDs in low-
and middle-income countries, therefore accelerating Universal Health Coverage and
achieving Sustainable Development Goal 3. The report sets out six building blocks,
accompanied by country examples, to help policymakers realize the full potential of digital
technology to strengthen their health systems and accelerate universal health coverage:
1. Policy makers need to prioritize, formulate and coordinate national digital health
strategies.
2. Legal frameworks are essential to protect patients while enabling innovation.
3. Standardized infrastructure allows information to be shared and used across the journey of
patients with chronic diseases such as NCDs.
4. Interoperability between diverse digital health solutions and data sources is a must to
enable coordinated NCD management.
5. Partnerships combine expertise, assets, and ideas to amplify the scale and impact of
successful digital health solutions.
6. Sustained financing is mandatory to scale successful digital health solutions.
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Subgroup on Operational Research
Lead authors:
Paul Saundersona & Lance Wallerb
aAmerican Leprosy Missions (ALM), Greenville, South Carolina, USA
bEmory University, Atlanta, Georgia, USA
Introduction
Operational research is a type of research that seeks to improve health outcomes by enhancing
the efficiency or reach of currently available tools rather than by developing novel ones. The
methodologies employed may be similar to those used in other types of research, such as
comparing an intervention arm (e.g., through a new way of organizing one aspect of a
program) with a control arm. Or, the method may be more specifically operational, e.g.,
examining the feasibility of expanding the use of a proven intervention such as post-exposure
prophylaxis (PEP),24 or examining the reasons behind a certain operational problem such as
why some people do not complete treatment as prescribed.25 Operational research can thus be
applied to a wide range of program components.
Priority research topics
In discussing strategies to reach zero leprosy, the Operational Research Subgroup of the
Global Partnership for Zero Leprosy (GPZL) Research Agenda Working Group recognized
that certain operational issues assume greater significance. The Subgroup therefore focused
on six priority topics: mapping, data management, monitoring and surveillance, health
systems strengthening, drug-resistance surveillance, and active case-finding. While the use of
digital tools and the use of mathematical modeling are also important aspects of operational
research, these topics were examined by separate GPZL subgroups and are discussed in their
respective reports.
MAPPING
Mapping disease incidence (to focus prevention) and prevalence (to focus treatment) has been
widely used to display the geographical distribution of several neglected tropical diseases
(NTDs). Analytic tools are increasingly available, but much of the hard work in mapping
involves collecting reliable patient and disease data in an appropriate format and linking these
to data relevant for operational research (e.g., data on transportation, logistics). Such data are
often available from multiple sources and in multiple formats but can be linked via their
geographic locations. Two enabling technologies include geographic information systems
(GISs) and location-based services (e.g., global positioning systems [GPS]). GISs enable
combination of disparate data by linking locations, while GPS links detailed and reproducible
location data to observed health measures.26,27
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In addition to technological support for mapping, the past several decades have seen a
rapid increase in the development of statistical tools for the analysis of spatial and spatio-
temporal data. Mapping incidence and prevalence at the level of small administrative regions
and communities is particularly helpful for leprosy because of the highly focal nature of the
disease, which can result in high incidence/prevalence areas being isolated and surrounded by
lower background values.
Based on discussions with the Operational Research Subgroup, two general areas of
spatial statistical tools are of particular interest for enabling operational research: (1) the
detection of local concentrations of high local incidence/prevalence rates; and (2) given the
scale of spatial clustering, the development of focused and adaptive sampling methods for
efficient detection of local hot spots of disease. For the first category, two sets of spatial
statistical tools are particularly useful in leprosy surveillance: methods to stabilize rates of a
rare disease in small geographic areas and methods to detect spatial/spatiotemporal clusters
of locally high disease rates (hot spots). Both categories extend traditional epidemiologic
analyses into the spatial and spatiotemporal setting,28 and tools are becoming available for
their routine use in public health surveillance. Such methods are already used by the leprosy
research and surveillance communities,29–31 and a comprehensive review of the emerging
literature in this area would help consolidate methods and computational tools and move
results from the statistical/epidemiologic methodology literature into operational research for
leprosy surveillance and response.
Regarding the second category, most NTD mapping to date has involved sample surveys
of common diseases, which provide an estimated prevalence of disease for a given area (e.g.,
a district). However, leprosy is an uncommon disease, which usually occurs in clusters. While
some mapping has been done using routinely reported data, this may not adequately reflect
the true burden of disease because of the variable quality of case-finding in most programs.
The challenge of efficiently sampling a large geographic area to identify isolated clusters of
an outcome of interest motivates a class of methods known as adaptive sampling, which was
originally developed as part of wildlife monitoring but has great potential for use in NTD
surveillance. The basic concept involves ongoing broad surveillance along with increased
efforts for areas indicating initial evidence of high rates, areas of historically high rates, or
areas containing a signature of risk factors indicative of higher local rates. Research is needed
to tailor such approaches to routine use for NTD surveillance, but promising applications
exist for Loa loa detection,32,33 and Chagas disease surveillance.34
Based on discussions within the Subgroup, the time is opportune for moving tools from
the statistical and epidemiological methods research space into routine practice in leprosy and
NTD surveillance to allow development of focused, actionable, and sustainable surveillance
protocols for leprosy detection, treatment, and prevention.
DATA MANAGEMENT
Data management is an important subject for operational research. All health programs
obtain, record, report, and analyze data for a variety of purposes, but this is rarely, if ever,
done without complications. Problems include too much or too little data, missing data, data
errors, reporting delays, and other issues. Even with good data, determining the best
indicators to monitor progress can be difficult and regulations regarding privacy need to be
incorporated in any system. The presentation of public health data for a wide range of users is
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now often enhanced by geographic display, making such presentations closely linked with
mapping (described above).
MONITORING AND SURVEILLANCE
Two kinds of monitoring are needed for leprosy prevention: program monitoring (to reflect
indicators of process, outcomes, etc.) and epidemiological monitoring (with proper
denominators and rigorous scientific inference).
The latter is essential to understand trends, without programmatic artifacts and errors. For
leprosy, having an accurate estimate of the true DALYs lost would also help raise funding
needed for impactful work. Epidemiological monitoring is also necessary to understand
the extent to which current interventions are having an impact, so that adjustments and
improvements can be made. This topic also overlaps with data management and mapping.
HEALTH SYSTEMS STRENGTHENING
Weak health systems can pose many barriers to effective leprosy control. All national
programs should therefore analyze the weaknesses of their leprosy control and health care
systems and identify challenges and the opportunities.
Health Systems Strengthening (HSS) in leprosy should aim to:
. Achieve effective and sustainable leprosy control towards zero leprosy among high and
low endemic settings.
. Be integrated with general health care systems.
. Contribute to the broader goals of universal health coverage.
Operationally, health systems interact in all areas of leprosy control measures: case detection
(including special efforts such as contact tracing, etc.), effective treatment (including follow
up during the post-multi-drug therapy [MDT] period), improved implementation of quality
disability interventions, and improved initiation of prevention activities (including
chemoprophylaxis). Therefore, HSS research should be viewed as a cross-cutting issue in
any kind of operational research undertaken to reach zero leprosy.
A WHO handbook describes six building blocks of health systems:35
. Service delivery.
. Health workforce.
. Health information systems.
. Access to essential medicines.
. Financing.
. Leadership/Governance.
Although the handbook focuses on the health system as a whole at national level, each
component can (and should) be looked at more narrowly from the perspective of a particular
program or locality. For example, data management and mapping are clearly part of the
health information system, while case-finding activities depend on the skills and availability
of the health workforce.
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Other issues related to the health workforce with implications for leprosy include:
. Different case-finding methods, including contact examination and the provision of PEP.
. The increasing recognition of counseling as a necessary service, particularly for all new
cases.
. The need for post-MDT surveillance and disability prevention.
Another important issue is surveillance. Research on the best methods will be a powerful tool
for advocating for financing and the political commitment to achieve zero leprosy.
R2STOP, an NTD research initiative, has identified implementation research associated
with contact management and chemoprophylaxis as their primary goal for stopping leprosy
transmission. In recognition of that goal and to align with the overall operational research
agenda of GPZL, the priority research areas of HSS should focus on these challenges, with
leprosy a mainstreaming agenda in their objectives, processes, and outcomes.
In addition to specific components of each of the health systems building blocks, several
major overall research areas for leprosy can be identified. These include
. Public and private partnerships (involving all providers) in implementing extended contact
surveillance with integrated approaches of case detection, prevention of disability
activities, follow-ups, and prophylaxis.
. Efforts to influence policy support to institute community participation (including co-
financial support) in routine care (including referral, follow-ups, and counseling).
. Integration of leprosy information (individual and consolidated) into national digital
platform (e.g., DHIS2) for monitoring and decision making.
Specific questions can be formulated for each area in conjunction with other priorities of
operational research, suitable in the time and context.
DRUG-RESISTANCE SURVEILLANCE
Drug resistance is a potential disrupter of any communicable disease control/elimination
program. Although the number of leprosy samples so far tested is low, results suggest that
drug resistance is not currently a serious threat to leprosy control.36 However, surveillance
measures are urgently needed to recognize drug resistance and enable immediate treatment to
prevent its spread and reduce its impact on efforts to attain zero leprosy.
Basic research is needed for improved methods of testing for drug resistance, especially
methods that can be used in less sophisticated and more peripheral settings, such as district
hospitals or health centers, as have been established with tuberculosis. Another research need
is the development of a test for resistance to clofazimine. Whole genome sequencing will
also be useful to identify further variations between drug-resistant and sensitive strains of
M. leprae that may be useful as molecular signatures for drug resistance under routine
conditions. Research could also be initiated to identify relevant genetic mutations in other
genes such as rpoA, rpoC, and other mechanisms of drug resistance.
Operational research is needed in two key areas: first, the development of improved
sampling procedures from new cases to properly monitor the rate of primary resistance to
rifampicin; and second, improved monitoring of treatment outcomes in cases showing
rifampicin resistance to determine the efficacy of second-line drug treatments for resistant
cases.
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ACTIVE CASE-FINDING
Finding incident cases of leprosy is currently the basis for control and elimination methods, as
mapping leprosy trends and implementing chemoprophylaxis for contacts both depend on the
identification of new cases. Many methods of active case-finding have been used in a variety
of settings, so determining the best approach for leprosy prevention is the primary operational
research question.
Contact examination has generally been a traditional component of leprosy control
programs and is recommended by WHO. The study in Nigeria mentioned above found
contact examination to be the most cost-effective method of identifying new cases. This
approach is now widely used, especially in settings where chemoprophylaxis is being
provided to contacts not found to have active leprosy.
More recently, attention has been paid to the possibility of integrated diagnosis and
management of a range of skin diseases within the NTD field.37,38 In this approach,
community health workers could identify suspect cases (using a tool such as the NLR
SkinApp, or the WHO guide on recognizing skin NTDs) for later confirmation and treatment
by experienced staff.
Studies on how to overcome health workers’ unfamiliarity with the basic signs of leprosy,
particularly in low-endemic settings, are currently underway in Cambodia.39,40 A new
approach to early diagnosis— retrospective active case finding (RACF), which uses small
mobile teams—was developed in the country. With RACF, previously diagnosed leprosy
patients are traced and their contacts screened through “drives.” This approach appears feasible
and effective in detecting new leprosy patients among contacts of previously registered
patients. However, a well-maintained national leprosy database is essential for successful
contact tracing. Therefore, passive case detection through routine leprosy surveillance is a
precondition for efficient RACF as the two systems are mutually enhancing. Together, these
two approaches may offer a promising option for countries with low numbers of leprosy
patients but evidence of ongoing transmission. The impact on leprosy transmission could be
further increased by the administration of single dose rifampicin as PEP to eligible recipients.
The following six methods of active case detection* have been generally used:
. House-to-house approach. This approach is useful in high endemic areas. Its guiding
principle is that every household should be visited and suspected cases defined in advance.
Awareness activities with information directed to the public are needed before such a
campaign can be conducted. Adequate resources should be allocated for information,
education, and communication (IEC); for training (and honorarium) of staff performing case
detection; and for confirmation. The search team should include a trained health worker plus
two ASHA volunteers (one female and one male), who have been provided general tools for
suspecting leprosy. The team should visit and examine suspected cases and refer them to the
nearest (ideally within walking distance) health facilities for evaluation on the same day or
within the next 1–2 days. Health facilities should include trained staff to examine individuals
for confirmation; slit smear laboratory capacity should also be available.
. Campaign-based approach. The campaign approach may be helpful in moderate or low
prevalence areas. As in a skin camp approach, in a campaign-based approach the public is
*Descriptions provided by Dr. Narayan Dharmshaktu.
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informed of the outreach in advance and invited to a location such as an open-air market
(haat bazaar), health camp, school, or other village site where individuals can be examined
by a trained physician and a skin smear slide can (optimally) be taken. Advanced
distribution of information to community members is essential under this approach. This
approach can also be combined with active house-to-house search approaches.
. Index case-based active case detection. This approach is useful in low endemic areas,
including areas where elimination is close to being achieved. The index case method can
also be combined with the campaign approach in low endemic areas but good IEC must be
conducted in advance to inform people when and where to report. This approach can also
be applied in migrants populations, such as human settlement areas near industrial and
construction projects. For large villages, this approach should aim to reach at least 100
households around index cases (25 households in each direction), including the relatives
settled in the village. If a village is smaller than 100 households, the full village should be
examined. For migrant and human settlement populations, the same strategies should
apply. While the index-case approach is cost saving, it has the disadvantage of incomplete
coverage and thus the likelihood of missing cases.
. Incentive-based case detection activities. For this approach, case detection is done
throughout the year and can involve community level health care volunteers who are paid
an incentive for each confirmed new case they identify. It can also involve patient
motivation through monetary incentives if patients are confirmed as having leprosy at a
health facility or with incentives for free evaluation and advice for patients suffering from
other skin diseases. Incentives can also be provided to individuals who bring suspected
cases for confirmation, which can serve as additional motivation for the general population
to report to the health facility. This approach may be useful in areas with literate people and
very good health infrastructure.
. Household healthy contact examination. This approach is generally recommended as part
of both routine leprosy program activities and active and passive case detection
approaches.
. Mixed approach. Combined approaches for active case detection can also be done
by programs to enhance the yield and improve cost effectiveness. Examples include
(1) a house-to-house approach, along with a campaign approach with or without incentive;
(2) a house-to-house approach with index case-based approach with or without incentive;
(3) an index case-based approach with a campaign approach with or without incentive; and
(4) an index case-based approach with an incentive approach. Each approach may be
useful if it is carefully planned and includes adequate supervision and monitoring within
the available resources.
Operational research could help to identify which method(s) are best in various situations.
Additional suggested operational research questions
Subgroup members suggested several other questions on issues that could potentially be
addressed through operational research, but these were not discussed in detail. Examples
include the following:
. What is the best approach for monitoring and treating nerve function impairment during
anti-microbial chemotherapy? (more applicable to discussions on disability).
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. What strategies should be used for patients with anergy to M. leprae who are likely to
require prolonged protection against re-infection or relapse?
. How can the concentration of environmental M. leprae be reduced in neighborhoods of
patients newly started on MDT?
. What is the weight of disability among persons affected by leprosy, using the Global
Burden of Disease (GBD) criteria?
Discussion and conclusions
Operational research can potentially cover a wide range of topics. The Subgroup has selected
a few that seem of particular relevance to achieving zero leprosy. Data management is central
to any public health program and is closely related to program monitoring and surveillance.
New technology has made the display of geographical data an ideal way to present large
amounts of information in a user-friendly manner for planning and decision-making.
Therefore, the operational research agenda relating to data management and mapping is likely
the area of most immediate importance to zero leprosy.
HSS is an overarching concern, related to important Sustainable Development Goals such
as Universal Health Coverage and ending the epidemics of certain infectious diseases. Any
studies working towards zero leprosy should be aligned with other efforts to strengthen health
systems.
Monitoring and managing drug resistance is an important area for research to prevent the
effectiveness of standard treatment from being compromised.While drug resistance in leprosy
is not currently a problem, it has the potential to undermine any work unless recognized.
A final priority area for operational research is active case-finding, which should be
designed to be as efficient as possible. Virtually all interventions on the road to zero leprosy
depend on finding index cases as a first step, so even small improvements in this area may
have beneficial outcomes.
Subgroup on Diagnostics
Lead authors:
Milton Moraesa & Malcolm Duthieb
aOswaldo Cruz Institute, Rio de Janeiro, Brazil
bInfectious Diseases Research Institute, Seattle, USA
Introduction
Although leprosy is caused by an infectious agent (Mycobacterium leprae or M.
lepromatosis), most of the heavily exposed population—the household and family members
of patients—will not develop leprosy during their lifetime. This group is considered at highest
risk for developing leprosy, but only 3%–5% will progress to the disease. Inherent to the
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current method of diagnosis of leprosy (i.e., detection of clinical symptoms such as skin patch
with loss of sensation, enlarged peripheral nerves), the disease is often diagnosed late.
Furthermore, although multidrug therapy (MDT) is effective, the number of new cases has
been stationary for the past 15 years—indicating that treatment does not block transmission.
In the past 25 years, immunoprophylaxis (with BCG vaccination) and, more recently,
chemoprophylaxis (e.g., single-dose rifampin [SDR]) have proved effective in preventing
leprosy in household contacts. Indeed, the 2018 WHO guidelines support this
chemoprophylaxis approach, which is likely to be a successful, short-term strategy aimed
at identifying new cases and treating healthy social and household contacts to impact
incidence. Nevertheless, efforts are clearly needed to improve early identification of leprosy
patients and to identify and treat infected persons—especially in low-to-middle endemic
areas where the use of large-scale chemoprophylaxis would not be cost-effective in
controlling transmission and reducing incidence. To reach these goals and contribute to zero
leprosy, progress is needed in clinical and laboratory-based diagnosis as well as translation of
the latter to rapid, user-friendly field tests.
Overview and current activities regarding leprosy diagnostics
Over the past 40 years, biochemical studies identifying PGL-I, the sequencing of the
M. leprae genome, and consortia such as the Initiative for Diagnostic and Epidemiological
Assays for Leprosy (IDEAL) have been landmarks in the development of leprosy diagnostic
tests. Initially, detection of humoral and cellular immune host-derived biomarkers with
ELISAs were used for detection of antibodies and cyto/ chemokines, respectively,41 whereas
molecular diagnostic assays were applied to detect pathogen-derived molecular (DNA/RNA).
More recently, for both host immune response-based assays as well as PCR-based assays,
technological advances are enabling better performance as well as an improved, minimally
invasive point-of-care (POC) format, through novel versions of the above-mentioned
techniques.42–45 Comparison of test platforms as well as large scale evaluation in multiple
endemic areas have been widely investigated for antibody-based tests,46 and the performance
of anti-PGL-I Ab based assays has been extensively described in the literature over several
decades.47 However, for pathogen-based qPCR assays as well as cellular immunity-based
rapid field-tests, although both field-tested in multiple areas with different levels of
endemicity,42,43,45 there have been few independent and consistently replicated results of
large sample size in coherent experimental designs in multicenter studies.
In several studies, data have been presented on pathogen detection using qPCR with
different targets,48 host immunity-based serological assays based on using either PGL-I or
NDO-LID,49 or cellular assays based on cytokine/ chemokine release assays.42,43 There is
vast evidence indicating that anti-PGL-I IgM or NDO-LID can be used in multibacillary
(meaning smear-positive, BL and LL cases) leprosy diagnosis, although seropositivity in
endemic areas can be found in numerous individuals who will never develop leprosy.
However, PCR improves identification of paucibacillary (meaning smear-negative, TT and
BT cases) leprosy as complementary to histological analysis.50 Moreover, combined
detection of humoral (antibodies) and cellular (cytokines) biomarkers significantly improves
their diagnostic potential, for both types of leprosy.43 Although most of the current products/
tests have been developed “in house,” large-scale (population-based) studies using a rapid
test to detect anti-M. leprae antibodies are currently ongoing (for example, the EDCTP-
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funded PEOPLE study). Notwithstanding the fact that rapid tests detecting cytokines/
chemokines were field-tested in areas on three continents where leprosy is still endemic,43
larger scale studies are needed to provide proper sensitivity and specificity data.
Among the challenges to leprosy diagnostics that should be the focus of research, the
Subgroup on Diagnostics of the Global Partnership for Zero Leprosy (GPZL) Research
Agenda Working Group outlined the following:
. The bacteria do not grow in vitro, in regular culture media.
. There is no definitive gold standard method for diagnosis.
. Bacteria silently infect nerves and skin cells, subverting immunological responses; hence,
there are few clear early signs of the disease that could distinguish active disease from
infection.
. There is no reliable marker to estimate infection and risk to disease progression.
. Among clinical forms of paucibacillary leprosy, the bacteria are virtually undetectable
using any testing techniques, although qPCR has demonstrated advances in sensitivity. In
addition, indirect methods based on simultaneous detection of host humoral as well as
cellular immune response directed against the bacteria provide promise as new tools.
. Clinical presentations among persons with leprosy differ widely, and several other diseases
present the same phenotypes—especially for the paucibacillary forms.
The Subgroup outlined two main diagnostic-related needs to achieve zero leprosy:
1. The ability to conduct early and specific diagnosis of leprosy and M. leprae infection to
block transmission using affordable, rapid POC tests in low-resourced settings.
2. The ability to screen exposed individuals to detect those who are infected. The use of
chemo- and immuno-prophylaxis (see report from Subgroup on Vaccines) in low-to-
middle endemic areas could help identify this group more precisely in the future.
Research priorities and key questions
POTENTIAL USE OF DIGITAL TECHNOLOGIES TO HELP IMPROVE CLINICAL
DIAGNOSIS
Five clinically recognized forms of leprosy are classified by Ridley and Jopling.51 In a group
of more than 1000 patients referred to a center with expert dermatologists, 90% were
diagnosed based on clinical features without skin biopsies for histological or molecular
analysis, indicating that intensive education is necessary to train experts for field
identification.52
Laboratory tests are not currently available to confirm either tuberculoid (TT) or
borderline-tuberculoid (BT) leprosy. The bacteria are not detected in slit skin smears from
lesions or other sites (ear lobes, knee, or elbow). The detection of the bacilli is possible in
mid-borderline (BB), borderline-lepromatous (BL), and lepromatous leprosy (LL) patients.
Thus, when multibacillary leprosy is suspected and microscopy analysis is available,
diagnosis is easier. Indeterminate leprosy is considered to be an early form of leprosy, which
progresses towards either the tuberculoid or lepromatous pole.
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 Key questions
– Could the use of high-resolution images and artificial intelligence improve
confirmation of suspected leprosy?
– Could artificial intelligence be used to screen skin biopsies using hematoxylin and
eosin (H&E) stains or slit skin smear slides for unrecognized patterns to help detect
tissue patterns or bacilli to improve diagnosis?
– Could cutaneous thermography be used as a complementary diagnostic method, with
or without ultraviolet photography? Thermography is capable of rapidly and
dynamically measuring the thermal energy of large areas of the skin through the
generation of images up to 1 million tones, representing differences of up to 0·018C. It
is a non-invasive, safe, and inexpensive technique. It would also make it possible to
remotely perform leprosy diagnosis in the most prevalent and poorest areas of the
world by sending images to reference centers.
NUCLEIC ACID-BASED TESTS
qPCR is being tested to confirm disease among paucibacillary patients. However, two main
issues need to be addressed to validate its use for disease confirmation: (1) several different
targets are available; and (2) most of the published qPCR data use research reagents and not
GMP products, which are designed for diagnostic purposes.
 Key questions
– Is there a method that could improve sensitivity and specificity in qPCR, including
reproduction of results? There is an urgent need for independent confirmation, larger
sample sizes, and combination of the best methods or mechanisms to harmonize
testing of different assays in different laboratories using external quality assessment
(EQA). In this regard, minimal requirements for best practices in qPCR in leprosy
diagnosis are needed. While specificities from different countries should be
considered, tests should be globally validated.
– Are better sampling methods available for direct/indirect detection of M. leprae or
DNA/RNA for use in diagnostic confirmation? Current methods rely on slit skin
smears and biopsies that are invasive and painful. Novel, less invasive, and affordable
methods are needed.
– Could other diagnostic methods be developed? The use of loop-mediated isothermal
amplification (LAMP) in leprosy molecular diagnosis is a relatively new DNA
amplification technique. Because of its simplicity, ruggedness, and low cost, LAMP
could be soon the method of choice for molecular diagnosis of leprosy but needs
extensive validation.
DRUG-RESISTANCE SURVEILLANCE
The development of primary resistance, especially for rifampicin, depends on treatment
adherence and completion rates for multibacillary cases. It is estimated that resistance is
increasing in different countries, although no systematic surveys/queries have been
performed. PEP protocols are spreading, and their impact on drug resistance needs to be
evaluated in the long term.
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 Key question
– Is the number of M. leprae resistant strains increasing, especially in endemic
countries?
– Are there other mechanisms for drug resistance, especially for clofazimine?
REACTIONS AND RELAPSES ( INCLUDING IN THE CONTEXT OF RESISTANCE)
Leprosy is a phenotypically diverse disease, and patients can undergo reactional episodes.
One of the most difficult issues is to discriminate relapses from reactions. Since reemergence
of the disease could be associated with resistance, direct screening is necessary to ensure
adequate treatment.
 Key questions
– Since qPCR or other molecular available techniques could be developed to directly
detect leprosy, as well as primary resistance to avoid ineffective treatment, is it
possible to develop a duplex or triplex qPCR also targeting the most frequent resistant
SNPs in rpoB?
– Could a new test be developed to detect bacterial viability? The direct detection and
estimation of molecular bacilli viability in fresh or fixed clinical samples would help
improve management of relapse cases (live mycobacteria) by distinguishing from
reactional states (dead mycobacteria).
– Concerning reactions, is it possible to define markers or a score to estimate the
patient’s risk of developing reactions?
DIAGNOSTIC TEST BASED ON DETECTION OF HOST IMMUNITY
Serological methods of detecting antibodies against M. leprae antigens such as NDO-LID or
PGL-I are not sensitive enough to detect paucibacillary leprosy. Besides, the presence of anti-
M. leprae antibodies is not predictive for disease. Current strategies such as detection of
blood-based cytokines by POC lateral flow assays offer diagnostic advantages and have been
tested in different countries. These strategies should be further evaluated in larger study
designs. For serological assays, some strategies can be used to achieve specificity and higher
sensitivity. These include (1) employing conformational or linear immunodominant epitopes
selected from products of the patient’s immune response and (2) using these epitopes as bait
for specific antibodies on label-free biotechnological platforms.53
 Key questions
– Can large scale multi-center studies be undertaken to validate the diagnostic potential
for MB and PB leprosy of POC lateral flow assays for (simultaneous) detection of
multiple cytokines/ chemokines and provide proper data on specificity and sensitivity
of lateral flow assays, using a defined biomarker signature, including markers for
humoral and cellular immunity? Could treatment response be monitored in the same
way?
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OTHER DIAGNOSTIC ISSUES
The use of host genomics has pinpointed novel pathways that are activated or deactivated
upon infection either in blood or tissue (skin and nerves). Also, host SNPs have been
identified as being associated with disease outcome.54
 Key questions
– Although a panel of blood-based host transcriptomic biomarkers has been described,
can more extensive data be obtained (particularly data on infected individuals
developing disease) in order to determine markers associated with (early) disease?
– Can a panel of host SNPs be used to estimate the risk of developing disease?
There are no tools, culture media, or techniques available to aid M. leprae growth, making the
identification and characterization of M. leprae difficult. Recently, tick-cell lines have been
described as tools to grow M. leprae.55
 Key question
– Would the use of tick-cell lines be feasible for confirmation of M. leprae diagnosis?
– Would their use be feasible for antibiotic resistance and drug discovery screening?
TESTING FOR INFECTION
Achieving zero leprosy will require better tools for disease control. It will be necessary to
predict among the at-risk population which individuals have the highest chance of
progressing to disease. Defined markers are needed to test whether a specific panel, signature,
or response could anticipate leprosy progression among contacts or the general population. It
is important that these tools be used in the near future in low- and middle-endemicity
countries/areas where screening of at-risk populations prior to chemo- and immunoprophy-
laxis would be cost-effective.
 Key questions
– Could a panel of genetic polymorphisms or transcripts or metagenomic markers be
defined to scrutinize high risk contacts?
– Is it possible to have a next-generation skin test (for example, based on recombinant
proteins) to screen for infected people?
– Can novel, low-complexity lateral flow assays based on fingerstick blood provide a
means for POC triage testing for infection by measuring both antibodies and
cyto/chemokines in capillary blood?
– Can a combined field-friendly test with a smartphone app be developed for follow
up of at-risk individuals and patients to increase testing and population coverage in
leprosy endemic areas.
NON-HUMAN RESERVOIRS
Issues surrounding non-human reservoirs for leprosy deserve attention and may impact
diagnosis. Recently, armadillos and red squirrels were reported as natural hosts that also
develop the disease after infection with M. leprae or M. lepromatosis. These results have
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provided novel hypotheses concerning M. leprae transmission that could influence leprosy
epidemiology and control.
 Key questions
– Are there reservoirs and transmission routes other than human-human in leprosy? An
improved and integrated view of the natural course of the disease could help establish
life cycles.
– Does leprosy in non-humans exhibit an infection stage and later an active disease stage
(a two-step leprosy progression) that could be used as model of leprosy development?
– Could non-human models be tested for leprosy progression?
Genomics could be used to better understand phylogeography and perhaps depict novel
virulence factors. Whole, large-scale genomics could be used to help determine strains/SNP
type/haplotype associations isolated from different clinical forms of the disease.
Conclusions and recommendations
Early diagnosis can help stop transmission and improve leprosy control. Although novel
tools with the potential for use in leprosy control exist, they must be scalable, GMP
produced, field friendly (i.e. low complexity), low cost, and adaptable to different levels of
endemicity.
As research priorities to ensure the capability for early diagnosis needed to achieve zero
leprosy, the Subgroup on Diagnostics recommends the following:
. Diagnostic assays (qPCR for pathogen, host immune response assays, host transcriptomic
assays) should be harmonized and validated globally through multicenter studies. As part
of this effort, standardization and quality assurance programs should be implemented to
compare these tools, providing grants are available for these efforts.
. Less invasive sampling methods should be developed.
. Although reasonable sensitivity and specificity have been achieved with currently
available methods, new methods using biomarker discovery, mycobacteria viability, cell
culture, and risk factor modeling should be developed for improved (next-generation)
diagnostic tools.
. Transmission research (intermediary host, vectors) may impact diagnostics, epidemiology,
surveillance, and control and should be prioritized.
. Tools should be used either to confirm leprosy when patients present suspicious lesions or
to screen and follow-up high risk individuals.
Longitudinal studies will allow identification of better markers associated with disease
progression. Future studies should involve evaluation of several assays at different
laboratories/field sites globally using identical protocols and allowing overall accessibility in
open (multi-disease) platforms for independent confirmation and validation.
GPZL Reports on Research Priorities260
Subgroup on Post-Exposure Prophylaxis
Lead authors:
Christa Kasanga & Peter Steinmannb,c
aGerman Leprosy and Tuberculosis Relief Association, Wu¨rzburg, Germany
bSwiss TPH, Basel, Switzerland
cUniversity of Basel, Basel, Switzerland
Introduction
Early case detection and prompt treatment with multi-drug therapy are the cornerstones of the
World Health Organization (WHO) recommendations for leprosy control.56,57 The more than
200,000 new leprosy patients detected each year,58 of which 10% are children, indicate stable
and ongoing transmission of Mycobacterium leprae. One of the main challenges to
interrupting transmission is the disease’s long incubation period: around 5 years until clinical
and diagnostic symptoms appear.59 The risk of developing leprosy varies across contact
groups.60 Household contacts have the highest risk, and neighbours of infected individuals
have a risk more than four times higher than that of the general population. While no specific
vaccine is currently available, work on the first leprosy-specific vaccine is advancing.
Transmission of M. leprae can best be interrupted by introducing new preventive
interventions. Chemoprophylaxis in the form of single-dose rifampicin (SDR) given to close
contacts of leprosy patients reduces their risk of developing leprosy by 60%; when combined
with childhood Bacillus Calmette-Gue´rin (BCG) vaccination, this risk is reduced by 80%.61 A
large, double-blind randomized controlled trial in Bangladesh and a controlled trial in
Indonesia have provided the bulk of evidence,62–64 indicating that SDR may also reduce
transmission by killing M. leprae in exposed contacts. Before SDR is provided to contacts of
leprosy patients, they must be screened for signs and symptoms of leprosy and other exclusion
criteria through a clinical, non-invasive examination of the skin. Because of this component,
which is identical to active case finding, the implementation of a chemoprophylaxis
intervention contributes to early case detection. The possibility of inducing rifampicin resistance
in M. tuberculosis has been examined by a group of experts who concluded that this risk is
negligible—both on theoretical grounds and on evidence from the long-standing worldwide
practice of giving monthly doses of rifampicin for the treatment of leprosy.65 Implementation
research studies on how to best integrate contact screening and SDR distribution into routine
leprosy control programmes are currently ongoing in several countries.
History of leprosy post-exposure prophylaxis
Systematic reviews with meta-analysis showed that several chemoprophylaxis projects had
been conducted in the 1960s and 1970s using dapsone once or twice weekly for 2–3 years or
acedapsone every 10 weeks for 7 months; since the 1990s, SDR has been used.62,63 All
studies showed superiority of the intervention over placebo, with an overall reduction of the
leprosy new case detection rate (NCDR) of 40%–60% in contacts.
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The most important results concerning the efficacy of SDR in leprosy post-exposure
prophylaxis (PEP) were generated by the COLEP trial in Bangladesh.66 This trial was a
single-center, double-blind, cluster-randomised, placebo-controlled study that included
21 711 contacts of over 1000 recently diagnosed leprosy patients. The overall risk reduction
for contacts during the first 2 years after SDR administration was 57%; no further risk
reduction was found beyond those 2 years. The highest protective efficacy was found in non-
blood-related contacts, but the study was underpowered to evaluate the impact on particular
contact groups. The calculated number of contacts needed to be treated to prevent a single
case of leprosy was 265 after 2 years and 297 after 4 years.64 Childhood vaccination with
BCG also had a protective effect of nearly 60%, and when combined with SDR an added
benefit was observed resulting in a protective effect of 80%.67 Thus, there are strong
indications that SDR in leprosy PEP (SDR-PEP) helps to decrease the incidence of leprosy.68
Current and recent studies on leprosy PEP
INDONESIA (2014 – 2016 )
A recent study in Indonesia has shown that in hyper-endemic foci SDR-PEP given to
household contacts alone may not be effective.69 For high-incidence pockets (‘hotspots’) or
populations (‘hotpops’), a “blanket” or mass drug administration approach for SDR-PEP may
be more appropriate.68 The feasibility of a population-wide administration of SDR was tested
in a prospective follow-up study in a high endemic and isolated community in Indonesia. The
feasibility could be proven, but the need for adequate planning and additional investments
was highlighted.70 A follow-up of this study is needed to observe the long-term effect and
determine the conditions to sustain it.
LEPROSY POST-EXPOSURE PROPHYLAXIS (LPEP) ( 2015 – 2019 )
The LPEP program is currently ongoing in India, Indonesia, Myanmar, Nepal, Sri Lanka,
Tanzania, Brazil, and Cambodia. It is designed to evaluate effectiveness, impact, and
feasibility of contact tracing and SDR-PEP for contacts of leprosy patients under routine
program conditions.71–73 The core LPEP study explores the feasibility and impact of
combining three key interventions: (1) systematically tracing the contacts of newly diagnosed
leprosy patients; (2) screening the traced contacts for signs of the disease; and (3) administering
SDR to eligible contacts.71 The activities are implemented through established structures of the
national leprosy control programmes, with coordination and supervision support by
international partners. Interim results based on data from 5941 index patients (89.4% of
registered index cases) and 110 512 contacts eligible to receive SDR (785 refused) show that
the intervention is feasible in different settings and under varying circumstances. However, for
implementation of SDR-PEP on a greater scale and in multiple socio-epidemiological
conditions, more field-level evidence is needed about its feasibility and impact in settings with
different levels of leprosy endemicity, particularly low-endemic populations.
PEOPLE TRIAL (2018 – 2022 )
The PEOPLE trial will evaluate different modalities of PEP for leprosy prevention in
Madagascar and the Comoros,74 with the goal of identifying optimal target populations for
GPZL Reports on Research Priorities262
PEP. It is planned as a cluster randomized trial aiming to:
. Test the safety and efficacy of a higher dose of rifampicin such as single-double dose
(SDDR; 1200mg rifampicin per adult compared to 600mg rifampicin in the LPEP
program).
. Identify which approach for selecting contacts eligible for PEP is most effective in
reducing incident leprosy through four study arms:
* Control (no PEP).
* SDDR-PEP, only household contacts.
* SDDR-PEP, household contacts and anti-PGL1 positive village contacts.
* Blanket SDDR-PEP at village level.
In all four study arms, annual door-to-door surveys will be conducted covering entire villages.
All permanent residents will be offered leprosy screening. Risk ratios will be calculated for
leprosy based on (1) physical distance from the nearest index household, (2) proportions of
phylogenetically clustered patients, and (3) proportions of patients belonging to the social
network of another patient. Additionally, costs per person treated with SDDR-PEP for each
study arm will be calculated, and genotyping of bacilli on samples from all incident leprosy
patients will be conducted.
PEP4LEP (2018 – 2022 ) :
The PEP4LEP trial is an implementation trial in Mozambique, Ethiopia, and Tanzania.
This cluster randomized study will compare PEP effectiveness in terms of the rate of
leprosy patients detected and the delay in case detection through two SDR prophylaxis
interventions: (1) a community “skin camp” and (2) a health-center based approach that
treats household contacts only. Additionally, it will compare the feasibility of the two
chemoprophylaxis interventions in terms of cost effectiveness and acceptability. Both
interventions will use an integrated skin disease approach and rely on a validated skin
disease diagnosis app (the SkinApp) to facilitate diagnosis. Other skin issues, such as
common skin diseases, other neglected tropical diseases (NTDs) manifesting with skin
lesions, and HIV/AIDS-related skin diseases, will also be diagnosed and treated. A
capacity assessment will be used to evaluate the skills of health workers in using the
common skin approach in practice.
MALTALEP (2013 – 2019 ) :
Maltalep is a cluster randomized controlled trial comparing immunization with BCG alone
with BCG plus SDR in contacts of newly diagnosed leprosy patients. Contact groups of
approximately 10 persons were established for each of the 1500 leprosy patients enrolled in
the trial, resulting in around 15 000 contacts in total. BCG was administered to the
intervention group followed by SDR 2 months later. The control group received BCG only.
Follow-up was at 1 year and 2 years after intake. The primary outcome is the occurrence of
clinical leprosy within 2 years. Simultaneously with vaccination and SDR, blood samples for
in vitro analyses have been obtained from 300 contacts participating in the trial to determine
the effect of these chemo- and immune-prophylactic interventions on immune and genetic
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host parameters. Results of this trial will become available in 2019, after completion of
2 years follow-up for all participants.
PEPþ þ PROJECT (2017 – 2022 ) :
The PEPþþ Project uses a cluster-randomized trial design to compare the efficacy of an
enhanced chemoprophylaxis regimen (PEPþþ ) with that of SDR PEP in close contacts who
are seropositive for antibodies against the leprosy-specific ND-O-LID conjugate. PEPþþ is
a multi-dose regimen comprising clarithromycin and rifampicin. The PEPþþ intervention
will complement a novel, cluster-based blanket implementation of SDR PEP. Clusters in
the participating districts will be identified using geographic information system (GIS)
technology. Both approaches will be supported by optimized leprosy case detection and
treatment services, including health systems strengthening, contextualized community
education on leprosy, stigma reduction interventions, and involvement of leprosy-affected
persons in various roles in their communities.
Research priorities and key questions
BASIC EPIDEMIOLOGICAL DATA NEEDS
A detailed understanding of disease distribution is essential for planning interventions like PEP.
Leprosy prevalence and surveillance
While over 200,000 new cases of leprosy are reported each year, a number of countries to not
report to WHO at all, or only irregularly;58 in Brazil, India, and Africa high numbers of
hidden cases were observed.75–77 Leprosy control programmes are often insufficient in parts
of these countries or not established at all. Being a focal disease, national statistics are also
insufficient to identify priority areas for interventions. Activities like PEP should be
integrated into local health services or combined with other disease control programmes to
make them successful.68 Thus, prevalence studies and surveillance activities are increasingly
needed—especially in areas where leprosy reporting is insufficient.
 Key questions
– Where are the leprosy endemic areas?
– How do we define endemic, and how many hidden cases do we have?
Mapping of current and retrospective routine surveillance data
The AIM Initiative demonstrated that, based on routine (i.e., Ministry of Health) surveillance
data of diagnosed leprosy patients, digital maps can be generated with village-level accuracy.
These maps also enable the overlay of geo-referenced health facility locations to show the
availability of services related to the distribution of the diseases. Establishing a detailed
understanding of disease distribution is essential for planning PEP intervention.
 Key question
– What is the geospatial distribution of leprosy patients in endemic countries?
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LEPROSY PEP INTERVENTION
The most critical pending research questions for LPEP involve operational research on how
to design and implement the intervention itself.
PEP intervention effectiveness
To make an intervention like PEP successful, effective and feasible active case-
finding/contact-tracing approaches must be defined both for low- and high-endemic settings
and for existing and novel approaches. PEP can be combined with different, active case-
finding modes. Contact screening approaches that include households, neighbours, or social
contacts could be done by actively visiting the houses or by asking the contacts to visit health
care facilities. The screening could be done by volunteer health care workers or by experts
on a case-by-case basis or during screening drives. PEP also could be given in a blanket
approach, during “skin camps” or any other mass screening events. Many different
interventions are and will be tested in the near future, and a periodically updated review of the
evidence and coordination of studies is necessary to avoid duplication and identify optimal
protocols for individual country/region or district settings.
 Key question
– Which type of PEP intervention fits best with which epidemiological setting?
PEP effectiveness under routine conditions
Efficacy of PEP for contacts of leprosy patients has been proven in several studies under
research conditions. As countries transition to implementing such interventions under routine
program conditions, it is essential to monitor the effectiveness of this approach. Different
routine conditions should be distinguished (integrated vs. vertical, and/or NTD integrated vs.
TB integrated). Monitoring should also include good surveillance for adverse reactions.
 Key question
– How effective is PEP under routine conditions?
Detailed cost studies
To encourage ministries of health to introduce PEP as a routine approach in their countries,
cost-benefit information is essential. Evaluations should consider the costs for active case
finding and for PEP along with the individual, societal, financial, and other benefits. Cost
evaluation should be considered part of a wider elimination investment, as the long-term
perspective and elimination potential will be major drivers of cost-effectiveness.
 Key questions
– What are the costs of PEP?
– How cost effective are the different implementation approaches?
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Quality of leprosy screening by minimally trained staff
Active case finding and PEP interventions often rely on volunteer or paid community health
workers (CHW) and other minimally trained staff. These individuals are expected to remain in
their home village or neighbourhood, and usually work part-time. To assess their effectiveness,
it is essential to study the diagnostic accuracy (sensitivity, specificity, positive and negative
predictive value) of their activities, to determine necessary training and re-training schedules,
and to explore the problems and challenges they face in diagnosing leprosy.
 Key questions
– Is the quality of leprosy screening by CHW sufficient to justify their use in PEP
activities?
– If so, under what conditions?
Surveillance for rifampicin resistance in leprosy
Although the possibility of inducing rifampicin resistance in M. leprae and M. tuberculosis
has been estimated to be very low, surveillance to compare resistances in SDR and non-SDR
areas is needed. Particularly, samples and data from patients who develop leprosy or
tuberculosis after the SDR administration should be collected.
 Key question
– Does implementation of PEP lead to development of rifampicin-resistant leprosy or
tuberculosis?
Field-friendly diagnostic tests
The use of field-friendly, point-of-care (POC), rapid diagnostic test (RDTs) would facilitate
the diagnosis of leprosy under field conditions, particularly by non-medical staff such as
CHWs (see above). Issues surrounding the development, validation, and introduction of such
tests were examined by the Subgroup on Diagnostics and are very relevant to the success of
PEP activities.
 Key question
– What efforts are needed to ensure the development and validation of a field-friendly,
rapid diagnostic test to support minimally trained staff in the diagnosis of leprosy?
LEPROSY PEP FREQUENCY AND DRUG OPTIONS
Efforts are needed to address several research questions on PEP medication.
Frequency of SDR in high endemic settings
The efficacy of SDR has been shown to persist over a 2-year period, with no additional benefit
thereafter. The re-administration of SDR after this 2-year period could improve the effect, but
the true benefit of re-treatment remains unclear.
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 Key questions
– What is the additional benefit of SDR re-administration?
– Under which epidemiological conditions is re-administration of SDR justified?
Other drugs for PEP
The potential of drugs like moxifloxacin and bedaquiline or drug combinations for PEP
should be tested.
 Key question
– How effective are other (new) drugs for single and repeated PEP?
PEP for high-risk contacts
The efficacy of SDR to reduce the risk of developing leprosy is lower among blood-related
household contacts and other very close contacts compared to more distant contacts. Studies
are ongoing to address this issue (e.g., PEPþþ and PEOPLE, see above), but other
interventions should also be explored.
 Key question
– How can the efficacy of PEP for blood-related household contacts and other high-risk
contacts be increased?
Disturbance of gut microbiome through PEP
The use of antibiotics can disrupt the ecology of the human gut microbiome. It would be
useful to study the short- and long-term consequences of single-dose antibiotic use on the
human gut microbiome and its effect on diseases such as malnutrition, obesity, diabetes, and
bacterial co-infections.
 Key question
– What are the effects of SDR on the gut microbiome?
Combination of SDR and vaccines
Immunization of newborns with BCG improves the protective effect of SDR. The effect of
other vaccines, like newly developed TB vaccines, is unclear. The use of inactivated or
recombinant vaccines would allow for possible co-administration with SDR PEP. Vaccine
development issues were addressed by the Subgroup on Vaccines, but it is important to study
their use in PEP activities.
 Key question
– Which vaccines are useful in terms of immunoprophylaxis and could be combined
with SDR?
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TRANSMISSION
The impact of leprosy PEP interventions on transmission and thus toward zero leprosy can
only be fully appreciated based on an improved understanding of M. leprae transmission.
Increased knowledge on M. leprae transmission will also facilitate the design of targeted
interventions to interrupt transmission that complement early case detection and PEP. The
current state of knowledge on M. leprae transmission has been reviewed,78 and related
research priorities formulated.79 An overview of tools and strategies to end M. leprae
transmission, including through PEP, has also been published.80 Based on the above, four
research areas have been identified by the Subgroup as priority concerns for understanding
M. leprae transmission:
Human-to-human transmission (human reservoir)
Areas of interest include (1) biomarkers for all clinical and subclinical cases of leprosy as
well as biomarkers for asymptomatic carriers; (2) the role of colonization and route of entry
of M. leprae into the human host; (3) roles of co-infections on the entry/exit of M. leprae from
the human host; and (4) stages of pathogenicity of M. leprae to understand the migration (port
of entry to the site of initial lesion to point of exit) of the bacterium inside the human host.
Non-human reservoirs
Areas of interest include (1) distribution of M. leprae in armadillos in the Americas and
corresponding zoonotic potential; (2) role of other animals in M. leprae transmission;
(3) biological relationship between M. leprae and amoeba as well as arthropods; (4) presence
of M. leprae in the environment in different endemic settings; (5) genotyping to understand
the role of M. leprae strains found in the environment and those found in the population; and
(6) demonstrated viability of M. leprae in the environment.
Host–pathogen interactions
Areas of interest include (1) relationships between M. leprae genetic characteristic and
virulence, growth kinetics, drug resistance, tropisms for nerves, and the tendency to cause
reactions; (2) the role of host genetic risk factors in susceptibility and resistance to M. leprae
infection, clinical progression of leprosy, and reactions; (3) understanding how the immune
response affects the various manifestations of leprosy including establishment of infection,
progression of disease, nasal carriage, and reactions; and (4) understanding of the
similarities/differences between M. leprae and M. lepromatosis.
Transmission networks
Areas of interest include (1) collection of genome-sequenced M. leprae strains including
isolates from various origins (e.g., worldwide, paucibacillary patients) complemented with
detailed epidemiological data; and (2) genetic diversity of M. leprae from different sources
(e.g., patients, nasal carriers, zoonotic and environmental sources) and various settings (e.g.,
high and low endemic regions) to understand the transmission ecology at the community
level.
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Subgroup on Vaccines
Lead author:
Steve Reed
Infectious Disease Research Institute, Seattle, USA
Background
Several cultivatable mycobacteria have been evaluated for use in alternate leprosy vaccines.
In the South India trial, a group of recruits was immunized with Mycobacterium w, which has
been reported to provide protection in mice. Follow-up evaluations indicated that M. w
provided only 25·7% protection, lower than all other groups evaluated. Despite this
limitation, a large-scale, double-blind immunoprophylactic trial of an M. w vaccine was
conducted among index cases and their household contacts in Uttar Pradesh, India, between
1992 and 2001. The vaccine consisted of 1 £ 109 heat-killed M. w bacilli for the first dose,
with a second, half dose given 6 months later. When index cases alone were vaccinated,
protective efficacies of 43%, 31%, and 3% were reported after 3, 6, and 9 years, respectively.
When contacts alone were vaccinated, protective efficacies of 69%, 59%, and 39% were
observed for these time periods. When both patients and contacts were vaccinated, these
protective efficacies were 68%, 60%, and 28%. As has been found in other studies, the
vaccine efficacy was highest in children. Thus, the protective effect of the M. w vaccine was
sustained in Uttar Pradesh for a period of about 7–8 years. Despite the reporting of these
results in 2005 and the commercial availability of the vaccine (“Immuvac”), immunization
with M. w does not appear to have been evaluated in other leprosy-endemic regions and it has
not emerged as a common control or prevention strategy for leprosy.
Recent studies
† Indian Cancer Research Center (ICRC) bacilli
ICRC bacilli, which are cultivable mycobacteria of uncertain origin, probably belonging to
the Mycobacteria avium intracellulare complex, were also used in the South India trial as a
live vaccine following reported use of this vaccine candidate to protect mice. ICRC
immunization induced persistent lepromin conversion in LL patients, as well as inducing
lepromin conversion in previously negative healthy subjects. Of all the immunization
groups included in the South India trial, ICRC provided the best protection, at 65·5%, thus
indicating that the ICRC vaccine might be useful for control of leprosy. Again, however,
widespread use of ICRC for the prevention of leprosy has not been reported.
† Mycobacterium vaccae
Mycobacterium vaccae is a nonpathogenic species of the mycobacteria that lives naturally
in soil. In a trial conducted in Vietnam involving vaccination with killed M. vaccae alone
(108 bacteria), BCG alone, or BCG plus 107 killed M. vaccae, children living in close
contact with leprosy were enrolled. Although a cumulative 53% protection was observed
in the first 4 years and 81% in the second 4 years for the vaccine groups combined, there
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were no significant differences in protection afforded by each of the three vaccines
although it was suggested that immunization with killed M. vaccae alone provided
protection. The addition of a preparation of killed M. vaccae to BCG did not enhance
protection afforded over that observed by either vaccine alone.
† Mycobacterium habana
Based on the protection observed in mice and the induction of lepromin reactions in
monkeys, M. habana has also been proposed as a leprosy vaccine candidate. Among
individuals immunized with live M. habana vaccination in India, lepromin reactivity was
reportedly augmented. Although this finding suggested that M. habana immunization
stimulated specific cell-mediated immunity against M. leprae and indicated vaccine
potential, there have been no subsequent reports regarding the protective efficacy of
M. habana vaccination.
Taken together, several vaccine strategies centered on the use of whole mycobacteria have
been attempted; however, to date, none besides BCG have advanced into common use.
Although BCG vaccination has proven to be only partially effective, this important vaccine
must be maintained and kept available for applications in both TB and leprosy, at least for the
foreseeable future. As the number of BCG manufacturers continues to diminish, however,
supply is becoming a serious issue.
Information to date indicates that the ideal vaccine against leprosy would need to induce
strong, long-lasting T cell responses directed against M. leprae antigens, thereby limiting
infection, preventing disease, and reducing bacterial transmission to others. Not until recently
has it been practical to contemplate development and delivery of a new generation of vaccines
for leprosy. Key technological and conceptual advances that put this strategywithin reach stem
from enabling antigen discovery through molecular cloning techniques, most notably the
completion and publication of the M. leprae genome. Gene synthesis and antigen production,
previously an insurmountable problem when dealing with an organism never cultured in the
laboratory, are now achievable at scales appropriate for vaccine development. Of even more
critical importance is the recent availability of adjuvants to enable a new generation of T cell
vaccines. Evidence supporting the development of a defined leprosy vaccine came in part from
studies showing that immunization with crude antigen preparations derived from theM. leprae
cell wall, cell membrane, and cytosol can provide protection—building on data using whole
M. leprae for prophylactic immunization. Although developing usable vaccine from whole
cells or fractions thereof is not practical, these earlier studies demonstrated the potential, at
least in experimental models, of developing a vaccine against leprosy.
Over the past several decades, the number of examples of effective immunotherapy for
cancer and infection has been increasing. Concepts have evolved, along with more effective
diagnostic tools, from using immunotherapy primarily for treatment of disease to its use in
prevention approaches including post-exposure prophylaxis (PEP). This latter example is
particularly applicable to the development of leprosy vaccines for which susceptible
populations can be effectively targeted for introduction of safe and effective intervention
measures to prevent progression to disease as well as transmission to others.
Partially effective vaccine applications for leprosy have been employed for decades,
primarily in the form of different BCG vaccine products that vary widely in their composition
and potency. Nonetheless, such vaccines have been used in cases of paucibacillary disease
and, more recently, in contacts of multibacillary patients.
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Key outcomes
As better tools are now becoming available for early detection of infection withM. leprae and as
some degree of efficacy has been achieved using single-dose rifampin (SDR) for PEP, it is urgent
that new approaches to augment or replace chemo-prophylaxis to prevent disease progression
and transmission in exposed individuals. Until recently, immunotherapy options were limited to
BCG, which being a live vaccine is generally limited to a single application. Furthermore, BCG
availability has become a challenge as various facilities have stopped production.
Beginning in the 1990s, there has been a renewed effort to develop better leprosy vaccines
and two inactivated vaccines for M. leprae are now advancing: MIP, a whole-cell vaccine of
heat-killed mycobacteria (M. pranii, previously known as M. w); and LepVax, a multi-valent
recombinant protein formulated in a modern adjuvant. The latter contains a modern adjuvant
that has been used in more than a dozen vaccine candidates and is a safe and effective inducer
of durable T-cell responses.
Ideal properties of a leprosy vaccine include its:
. Safety in M. leprae-infected and -uninfected individuals.
. Capacity to induce both M. leprae-specific immune responses and durable anti M. leprae
immunity.
. Ability to be used in contacts, together with SDR, to inhibit transmission and disease
progression.
Potential applications of a leprosy vaccine include:
. Treatment shortening for paucibacillary (PB) treatment.
. PEP in leprosy contacts.
As of early 2019 the MIP vaccine candidate is undergoing further evaluations in India, and
the LepVax candidate will enter into Phase 2 evaluations in Brazil this year. Thus, including
BCG, there are now three potential vaccine candidates for use in a zero leprosy campaign. As
further clinical studies are designed and implemented, it will be important to carefully
evaluate safety and efficacy endpoints, including changes in neurological function.
Conclusions
In summary, never before have there been so many tools for the diagnosis, prevention, and
treatment of leprosy. The time is clearly right for a comprehensive and multi-faceted approach
to zero leprosy. Based on their reviews and discussions, members of the Vaccines Subgroup of
the Global Partnership for Zero Leprosy (GPZL) Research AgendaWorking Group havemade
the following observations regarding vaccine research towards zero leprosy:
1. Safety monitoring will be a critical component for evaluation of any vaccine/immu-
notherapy procedure in a PEP/therapeutic setting.
2. Regular updates are needed on the current status of the MIP vaccine and LepVax.
3. Coordination is needed with WHO regarding criteria used to make recommendations for
vaccine implementation.
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4. Inclusion of a range of early diagnostic tests will be important in vaccine trial design and
interpretation. Initially, these tests should be used not to include or exclude contacts from
vaccine trials but rather to advance understanding of disease, the diagnostic tests
themselves, and the optimal utility of a vaccine/immunotherapy.
5. Evaluation of clinical trial sites is critical to ensure adequate design/execution of studies in
areas where the need is highest and where a path towards approval has been defined.
6. Clarification is needed for study design and for the parameters used to evaluate vaccine
safety/efficacy.
7. One or more Target Product Profiles should be developed for vaccines, e.g., one for
shortening the duration of treatment for PB disease and another for disease prevention in
contacts.
Subgroup on Disability
Lead author:
Liesbeth Mieras
Netherlands Leprosy Relief, Amsterdam, The Netherlands
Summary
Leprosy is an important cause of preventable disability. Leprosy-related disability is not
limited to physical dysfunction but includes activity limitations, stigma, discrimination, and
social participation restrictions. Within the Research Agenda Working Group of the Global
Partnership on Zero Leprosy (GPZL), two subgroups were formed to address these issues.
The agenda for stigma and discrimination research was defined by the Subgroup on Stigma;
the Subgroup on Disability focused their work in the following two areas:
I. Preventing disabilities among persons affected by leprosy
II. Minimizing the impact of living with impairments due to leprosy
Much is known about these two main components of leprosy-related disability. Early
detection and treatment of both the disease and the reactions and nerve function impairment it
causes are critical to prevent disabilities. Effective strategies for preventing disability and its
worsening are known, and successful rehabilitation techniques are available. However, there
is much room for improvement in areas such as accessibility of services, effectiveness
(including cost effectiveness) of available services, and novel tools to improve current
practices. Increased understanding of the causes of disabilities and ways to optimize disease
management and improve inclusion is definitely needed to work towards zero leprosy.
The Subgroup identified several priority research topics under the two focus areas:
I. Preventing disabilities among persons affected by leprosy:
† Early detection of leprosy to prevent disability:
W Assessing the impact of case finding/contact tracing strategies on the prevalence of
leprosy-related disabilities among new cases.
† Pathophysiology, detection, and management of reactions:
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W Research on pathophysiological/immunological mechanisms of Type 1 and Type 2
reactions and nerve damage.
W Development and validation of diagnostic tools for the detection and measurement
of nerve function impairment.
W Promotion and facilitation of the use of available treatment for reactions and nerve
function impairment and identification of new treatment options.
II. Minimizing the impact of living with impairments due to leprosy:
† Number of people with disability due to leprosy and categorization and quantification
of their needs:
W Estimating the burden of disability due to leprosy.
† Prevention of disability and its worsening (POD):
W Research on the feasibility, effectiveness, and impact of POD strategies, including
self-care, physiotherapy, occupational therapy, and combined approaches.
† Rehabilitation services:
W Assessing the accessibility and effectiveness of physical rehabilitation services and
the provision of assistive devices.
† Community-based rehabilitation (CBR):
W Research on the effectiveness, feasibility, and social and economic impact of CBR
programs.
Some of these research needs can be addressed by large, population-based surveys. Such
surveys could be added to ongoing multi-center studies, if resources were added to ensure
sufficient capacity. Studies of reactions and nerve function impairment would require basic
pathophysiological/immunological lab research. Efforts to minimize the impact for people
living with impairments would require a targeted approach in areas with large numbers of
people affected by leprosy or where people are affected by multiple neglected tropical
diseases (NTDs).
Introduction
Although most leprosy-related disabilities are preventable, an estimated 2–3 million people
live with leprosy-related impairments. These impairments may or may not cause activity
limitations or restrict social participation, depending on the degree of severity and of social
stigma. If the psychosocial consequences of leprosy, such as exclusion, anxiety, and
depression were also considered, the number of persons affected could be much higher. This
is certainly the case if the impact on family members is taken into account.
Disability is more than physical dysfunction; it includes activity limitations, stigma,
discrimination, and social participation restrictions in interaction with contextual factors.
This is reflected in the WHO International Classification of Functioning, Disability and
Health (ICF) model of disability, which shows the relatedness of body structure and function
(and impairment thereof), activity (and activity restrictions), and participation (and
participation restrictions) (Figure 5). Future research therefore should address major
challenges at the national and international levels to ensure prevention of disabilities and to
minimize the impact of people living with disabilities by managing these in such a way that
their participation and inclusion in society is optimized.
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The Subgroup on Disability identified key research areas related to disability that are
needed to prevent and reduce leprosy and the consequences of the disease. As a basis of their
work, the Subgroup reviewed multiple strategies, including the Triple Zero Campaign of
ILEP, the ILEP Global Strategy, and the WHO Global Leprosy Strategy 2016–2020, along
with documents and developments in the field of neglected tropical diseases (NTDs) and
disability. The developments in the various disability-related task groups of the NNN Disease
Management, Disability and Inclusion (DMDI) Working Group were also considered. The
Subgroup also examined the recent work done by the Leprosy Research Initiative (LRI) to
draft an updated set of research priorities aligned with current developments in the field of
leprosy. For this effort, the LRI completed an extensive exercise that involved an inquiry
panel, focus group discussions, an e-survey, and a Delphi panel and included a wide range of
stakeholders (e.g. persons affected by leprosy, organizations working in the field of leprosy,
medical staff, policy makers, researchers etc.).
Goal of the disability subgroup
The goal of the research recommended by the Subgroup on Disability is to contribute to:
. Preventing disabilities among persons affected by leprosy.
. Minimizing the impact for people living with impairments due to leprosy by:
* Ensuring that persons with permanent impairments due to leprosy or other NTDs can
effectively manage their impairments and disabilities and have access to medical,
rehabilitation, and social services when needed.
* Improving social inclusion of all persons affected by leprosy through disability-
inclusive development.
Health condition
Body Functions
& Structure Activity
Contextual factors
Environmental
Factors
Personal
Factors
Participation
(disorder or disease)
Figure 5. WHO ICF model of disability.
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Research priorities
I . PREVENTING DISABILITIES AMONG PERSONS AFFECTED BY LEPROSY
. Early Detection of Leprosy to Prevent Disability
* Assessing the impact of case finding/contact tracing strategies on the prevalence of
leprosy-related disabilities among new cases
* The impairment status of a leprosy patient at diagnosis is known to be the most
important determinant for future impairment.81 However, the extent to which
different active case finding and contact tracing strategies contribute to a reduction of
leprosy related disabilities is unknown.
 Key question
– What is the impact of case finding/contact tracing strategies on the
prevalence of leprosy-related disabilities?
 Research to address the issue
– Operational research to assess the (cost-) effectiveness of case finding
strategies
– Mapping studies of leprosy patients and leprosy-related disabilities
. Pathophysiology, Detection, and Management of Nerve Function Impairment and
Reactions
* Pathophysiology of reactions and nerve function impairment
Research is needed on the pathophysiological/immunological mechanisms of Type 1
and Type 2 reactions and nerve damage (as well as neuropathic pain) in leprosy,
including the identification of factors associated with increased risk of reactions and
nerve function impairment. Someof these factors are known, such as the type of leprosy
and the time since completion of treatment.82,83 However, a better and more specific
understanding of mechanisms and risk factors is needed to improve management of
reactions.84–86 In addition, as neuropathic pain also importantly contributes to
disability, early recognition and improved management of such pain is needed.
 Key questions
– What are the pathophysiological/immunological mechanisms associated
with increased risk of reactions, nerve function impairment, and neuropathic
pain?
– What new and effective treatment options are available for the management
of neuropathic pain?
 Research to address the issue
– Basic pathophysiological/immunological lab research to identify risk factors
for reactions and nerve involvement
* Detection of nerve function impairment
Development and validation of diagnostic tools is needed to detect and measure nerve
function impairment (including silent neuritis) and reactions. Detecting nerve damage
as early as possible will greatly contribute to the prevention of disability. Nylon
monofilaments (Semmes-Weinstein monofilaments) and voluntary muscle testing are
current state-of-the-art tools that have been shown to correlate well with sophisticated
neurophysiological measures.87–93 Newer instruments have recently been evalu-
ated.94 Definitions for clinically relevant nerve function impairment are needed to
determine meaningful change.
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 Key questions
– How can the identification of Type 1 and Type 2 reactions be improved?
– Which simple, existing or new tools can provide the earliest detection of
neurological signs of leprosy and/or measure nerve function impairment?
– How can the use of these tools best be promoted and the capacity of health
care staff to use them be ensured?
 Research to address the issue
– Clinical research to test and compare new and existing tools to detect nerve
function impairment
– Implementation research to ensure the use of tools to detect nerve function
impairment by different health care providers
* Management of reactions and nerve function impairment
Efforts are needed to promote and facilitate the use of available treatment for
reactions and nerve function impairment and to identify new treatment options. Given
that reactions and neuropathy remain the leading cause of disability in leprosy,
promoting and facilitating the use of available treatment (steroids) remain top
priorities. Recent trials have established that a steroid regimen of 32 weeks to treat
nerve damage does not give added benefit over a 20-week regimen.95,96 A parallel
trial established that steroid treatment of newly diagnosed leprosy patients with sub-
clinical, small fibre neuropathy at the time of diagnosis does not reduce the risk of
long-term clinical nerve damage. Alternative drug treatments for Type 1 and Type 2
reactions may improve prognosis and reduce the risks inherent in long-term steroid
treatment. Research has shown that households affected by erythema nodosum
leprosum (ENL) face significant economic burden and are at risk of being pushed
further into poverty.97 However, more research is needed to explore this area and
identify solutions. Research on armadillos suggested that LepVax treatment might
restore some early sensory axonal function: when used as post-exposure prophylaxis,
it alleviated and delayed the neurologic disruptions caused by M. leprae infection.98
 Key questions
– What efforts are needed to ensure that steroids are available and used
properly and in a timely manner for the treatment of reactions?
– What are alternative, effective treatment options for the management of reactions?
– What are mechanisms of increased financial burden on leprosy patients and
their families due to reactions, and what are possible solutions to address
them?
– What could the role of LepVax be in the prevention and treatment of nerve
function impairment?
 Research to address the issue
– A survey to assess 1) the (national) guidelines on steroid use and the steroid
availability at national and peripheral levels and 2) the capacity of health
workers to use them.
– Qualitative research to examine patient and health care provider behaviour
when treatment of reactions is needed.
– A new Cochrane review of steroid and other drug trials for management of
reactions.
– An assessment on the benefits of alternatives to corticosteroids.
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– Health economics research to determine the risks for an increased financial
burden due to reactions.
– Qualitative research to determine solutions to prevent an increase of the
financial burden.
– Clinical trials to learn more about the effects of LepVax.
I I . MINIMIZING THE IMPACT OF LIVING WITH IMPAIRMENTS DUE TO LEPROSY*
. Number of People with Disability due to Leprosy
* Estimating the burden of disability due to leprosy and other NTDs or other diseases
that share cross-cutting issues with leprosy
Efforts to improve disability prevention and management for persons affected by
leprosy are hindered by the lack of data on the number of persons with disabilities in
general as well as the number with disabilities related to leprosy or other NTDs. The
disability grade at the time of diagnosis is usually the only disability factor that is
recorded in leprosy control. The type of disability and the worsening of disability during
and after treatment is usually not included in reports. A better understanding of the
magnitudeof the problemand the needs of thepeople livingwith impairments is required
to properly address them through program planning, using baselines for monitoring
outcome and impact of interventions as well as for advocacy and fundraising.
 Key question
– What is the burden of disability due to leprosy and other NTDs or other
diseases that share cross-cutting issues with leprosy?
 Research to address the issue
– Cohort study to determine the quantity of the increase of disability during
and after treatment.
– Mapping studies of people with disabilities due to leprosy and other related
diseases such as NTDs.
. Prevention of Disability and Its Worsening (POD):
* Research on the feasibility, effectiveness, and impact of POD strategies (including
self-care, physiotherapy, occupational therapy, and combined approaches)
Limited evidence is available on the added value of self-care groups and family support
for POD.99,100 More evidence, however, is needed on various POD approaches in
different settings and with other disabling diseases, especially regarding feasibility and
effectiveness, including cost-effectiveness. The local context, gender roles, living
conditions, existing barriers, and other factors for persons affected by leprosy all
determine the feasibility of disability prevention strategies. Novel techniques used in
wound care in general and in diabetic foot-care specifically can be beneficial for
personswith ulcers due to leprosy. Development of a protocol for combined self-care of
persons with leprosy-related and diabetic neuropathy would be important.
 Key questions
– What are the most feasible, (cost-) effective strategies for POD in various
settings?
*Stigma and discrimination are addressed in the report from the Subgroup on Stigma.
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– What new, effective treatment options for ulcers are available?
– Could alternative therapies contribute to increasing the quality of life for
people with leprosy?
 Research to address the issue
– Operational research; piloting of best practices for combined skin and wound
care, including M-Health approaches and self-management.
Qualitative research on the application of alternative practices to alleviate
pain symptoms and increase quality of life.
– Qualitative research on the perception and acceptability of POD strategies
and ulcer treatment options.
Health economics research to assess the cost-effectiveness of POD
strategies.
– Operational research piloting different wound treatment.
. Inclusive Rehabilitation Services
* Assessing the accessibility and effectiveness of physical rehabilitation services and
the provision of assistive devices for persons with leprosy-related disabilities within a
health system context
Rehabilitation services and the provision of assistive devices for persons with leprosy-
related disabilities are often organized in parallel to the existing general health
services. Evidence showing the (cost-) effectiveness and feasibility of integrated
services would help to convince stakeholders of the benefit of providing persons
affected by leprosy with the services they need within the existing health system.
 Key question
– How can rehabilitation services for persons affected by leprosy be organized
most effectively within the existing health system?
 Research to address the issue
– Health systems research to determine the best way to integrate rehabilitation
services for persons affected by leprosy.
Health economics research to determine the cost-effectiveness of integrated
services.
Mapping of rehabilitation services.
. Community-based Rehabilitation
* Research on the effectiveness, feasibility, and social and economic impact of CBR
programs
The evidence base related to the impact of CBR remains limited, both in terms of
quantity and strength of design.101
 Key question
What are the characteristics of sustainable, effective, feasible, and impactful
CBR programs to address the needs of persons affected by leprosy?
 Research to address the issue
Qualitative research to determine the needs of persons affected by leprosy.
Operational research piloting different CBR approaches.
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Baseline information needed
An inventory of the existing leprosy research structures (e.g., the research groups involved in
studies on leprosy, disability, and related issues) would help to clarify the capacity needed to
address the research priorities on leprosy-related disability. It would also help identify ways
to address various research needs through integrated studies.
Access to certain baseline data would be very useful for the research agenda on disability.
To help attain these data, the GPZL’s Operational Excellence Working Group could include
the following issues in an assessment of leprosy control programs:
. Post-multi-drug treatment surveillance.
. Availability of and accessibility to steroids; the use of thalidomide.
. The use of nerve function assessment tools.
. Geographic overlap with other NTDs.
. The accessibility to and the use of devices, such as prosthetics, orthoses, and auxiliary
devices.
. Best practices to address POD and minimizing the impact of living with impairments due
to leprosy.
Subgroup on Stigma
Lead author:
Wim H. Van Brakel
Netherlands Leprosy Relief, Amsterdam, The Netherlands
Introduction
Compared with other leprosy-associated issues, the topic of stigma and discrimination has
received little attention from the International Federation of Anti-Leprosy Associations
(ILEP) members, the World Health Organization (WHO), and national programs. Yet, it is
consistently the number one issue and challenge described by persons affected by leprosy in
most areas of the world. Discrimination and attitudinal biases are often mentioned as the
primary barrier to inclusion for persons with other disabilities and are a key topic in the
United Nations (UN) Convention on the Rights of Persons with Disabilities (CRPD). Stigma
is often the factor that turns an impairment into a disability and causes social exclusion. The
mental health consequences of living with disabilities and the associated stigma and
discrimination are increasingly an area of interest in the neglected tropical disease (NTD)
field.
Stigma is highly relevant in the context of the Global Partnership for Zero Leprosy
(GPZL), as zero discrimination is a declared goal. Moreover, stigma is a barrier to zero
leprosy due to its effect on leprosy prevention, treatment, case management, and prevention
of disabilities.
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To achieve zero leprosy and to have a meaningful impact on stigma and
discrimination, future research should address major challenges at the national and
international levels. The priorities for this research should fit with or optimally integrate
with those of the ILEP’s Triple Zero Campaign, the WHO Global Leprosy Strategy 2016–
2020, and the aspirations of the GPZL and the Neglected Tropical Disease NGO Network
(NNN). The GPZL Research Agenda Working Group’s Subgroup on Stigma examined
these reports to make an inventory of needs related to leprosy stigma and discrimination.
The Subgroup also drew on the report of a global research priority review conducted by
the Leprosy Research Initiative (LRI) in 2018 and considered the work of the various task
groups of the NNN’s Disease Management, Disability and Inclusion (DMDI) Working
Group, which has a Task Group on Mental Wellbeing and Stigma that works on related
issues.
Based on this review, the following were identified as important needs and challenges to
be addressed in the leprosy field related to stigma:
. Documenting (and mapping) the level of stigma in communities and health services.
. Addressing community stigma as a barrier to zero transmission, e.g., as a barrier to:
* Treatment seeking, early diagnosis, and disclosure.
* Treatment adherence.
* Prevention of disabilities.
. Addressing negative attitudes and behaviours against persons affected by leprosy as
barriers to inclusion in the community, with special reference to women and girls, and in
access to health services.
. Documenting the impact of stigma and discrimination on the mental health of persons
affected by leprosy (and other NTDs) and identifying and evaluating ways to prevent and
mitigate this impact.
. Mitigating the effects of stigma and discrimination among persons affected by leprosy
(especially internalized stigma) and among their family members.
. Validating stigma and mental health assessment tools from the NTD Disability and
Morbidity Toolkit in more leprosy-endemic countries.
. Applying the health-related stigma concept:102 pioneering joint stigma reduction
interventions for persons with NTDs and/or disability groups.
GOALS OF THE RESEARCH PRIORITIZED BY THE STIGMA SUBGROUP
The goals of the research recommended by the Stigma Subgroup are to:
. Reduce stigma as a barrier to treatment seeking, case detection, diagnosis, treatment
adherence, self-care, and rehabilitation.
. Mitigate the impact of stigma and discrimination on mental wellbeing and all aspects of
social participation among persons affected by leprosy.
. Increase active participation of persons affected by leprosy in leprosy services.
. Improve social inclusion of all persons affected by leprosy through disability-inclusive
development.
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Research priorities, current knowledge, and key questions
In 2018 the Leprosy Research Initiative (LRI), a combined venture of several ILEP partners
and other NGOs supporting work in the field of leprosy, conducted an extensive review of
leprosy research priorities that had been defined in 2013. Their efforts involved an inquiry
panel, focus group discussions, a global e-survey, and a Delphi panel. The purpose was to
draft an updated set of research priorities aligned with the current developments and
challenges in the field of leprosy. The effort involved a wide range of stakeholders, including
persons affected by leprosy, representatives from organizations working in the field of
leprosy, medical staff, policy makers, and researchers. The main questions identified were
1) which leprosy-related research topics are considered to be the most important and (2) how
are they ranked according to priority by the stakeholders?
The LRI results were grouped according to the three zeros in the ILEP Strategy: Zero
Transmission, Zero Disability, and Zero Discrimination. The Stigma Subgroup reviewed
these results and did not identify any major missing topics. The Subgroup then took the
top eight research priorities for Zero Discrimination from the LRI study and grouped them
into four major priority themes that could be studied together in large, coordinated multi-
country projects. Changes were made to the wording and emphasis of several of the
topics. The four priority themes are listed below, together with key research questions for
each.
1 . INTERVENTIONS TO REDUCE STIGMA AS A BARRIER TO ZERO LEPROSY
Several stigma interventions such as contact intervention, peer counseling, and socioeconomic
development have been tested.103,104 Also, the effectiveness of using “champions” and
involving persons affected by leprosy in stigma reduction have been demonstrated.105,106 The
positive effects of a sustained social marketing campaign in Sri Lanka have been shown, but
results in terms of stigma reduction were never measured.107,108 The effects of a multi-media
modified leprosy elimination campaign in India were measured but never published in a peer-
reviewed journal.* The interventions described in these studies should be tested in additional
settings and cultures, and ways to scale up such interventions should be investigated through
operational research. A few surveys have been done in recent years to document the types,
prevalence, and severity of stigma in leprosy-endemic countries.103,109–114 However,
such studies are needed in all leprosy-endemic countries and in countries and areas where
leprosy-related stigma is known to be a problem. Baseline data are needed for monitoring the
effect of interventions. It is important that such baseline and stigma monitoring studies
use standard tools. The Participation Scale115 and the 5-Question Stigma Indicators are
recommended in the Monitoring and Evaluation Guide that accompanies the WHO Global
Leprosy Strategy 2016–2020. These and a number of stigma-assessment tools have been
validated cross culturally,116–123 but additional validation studies are needed—especially
validation of the short 5-Question Stigma Indicators in the Monitoring and Evaluation Guide
and the SARI Stigma Scale.121 Stigma levels are known to vary significantly, even at local
levels, which has direct repercussions for targeting interventions.124 Stigma baseline studies
should also address health services-related stigma, which is still a common, but rarely studied
* http://www.comminit.com/bbcmediaaction/content/impact-data-bbc-world-service-trust-leprosy-project
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phenomenon in many leprosy-endemic countries. An instrument for this purpose was recently
developed and validated to assess attitudes of health care providers towards persons affected
by leprosy in southern India.125
Guidelines for participation in research studies have been formally adopted by WHO,126
but the implementation often has been rudimentary. It is essential for research projects to
include persons affected by leprosy among the investigators, where possible, and on steering
committees. Similarly, these persons should be involved in decisions that may impact them
and in the implementation of leprosy services. Studies examining how this can best be done in
various situations and the effects of this involvement are urgently needed.
Research into the effectiveness of stigma reduction interventions should include
feasibility, acceptability, and the impact of community involvement, skills building, and
empowerment and participation of persons affected by leprosy. Such studies should also
include cultural validation of tools to determine the level and type of stigma in communities
and health services and among persons affected by leprosy and to monitor and evaluate the
effect of the interventions.
 Key questions
– What is the effectiveness of various stigma-reduction interventions in different
settings, and which interventions can be used on a large scale?
– What is the prevalence of different types of stigma and their geographic distribution in
leprosy-endemic areas?
– How often and in what ways do stigma and discrimination against persons affected by
leprosy occur in the health services? How do stigma experiences develop over time?
– What are the effects of the participation of persons affected by leprosy in research and
health services? What are best practice models to implement this?
2 . UNDERSTANDING PERCEPTIONS OF LEPROSY AND
THE REASONS BEHIND THEM
Patient and community knowledge, beliefs, fears, and practices play major roles in the
perception of leprosy,116,127,128 in the perceived need for early diagnosis and treatment, and
in the prevention and management of disabilities.129–134 These factors need to be well
understood so that interventions targeted to specific beliefs and attitudes can be used instead
of generic messages.
Research is needed on the perceptions of the disease and explanatory models (personal
conceptualization of the cause, course, and consequences of leprosy). Research into
experiences with the disease and its consequences is also needed as a basis for developing
optimal communication and behaviour change approaches. A standard toolkit using mixed
methods should be cross-validated and adopted for studying the perceptions and explanatory
models regarding leprosy.
 Key question
– What do patients and community members know, believe, fear, and do concerning
leprosy that would be relevant for developing tools for health education and behaviour
change regarding stigma, disclosure, treatment seeking, treatment adherence, and
prevention of disabilities?
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3 . MENTAL WELLBEING OF PERSONS AFFECTED BY LEPROSY
The negative impact of having leprosy and leprosy-related visible and other disabilities and
especially of experiencing stigma and discrimination on the mental wellbeing of persons
affected by leprosy has long been recognized.135–139 However, population-based studies of
mental distress, anxiety, and depression among this population and their family members are
scarce. There is evidence that various forms of counseling can help greatly to mitigate the
mental health impact of leprosy.140–142 Studies are needed to examine the association
between mental distress, anxiety, and depression and various health and programmatic
outcomes, such as case detection, treatment adherence, self-care, and rehabilitation.
Studies are also needed on mental wellbeing of persons affected by leprosy and on the
associations between mental health, health care-seeking behaviour, and accessibility of
services (e.g., diagnostic or treatment delay, treatment compliance, participation in self-care
groups). Such studies should be part of or directly linked to intervention studies to prevent a
negative impact on and/or to improve mental wellbeing among those suffering from anxiety,
depression, or other mental health conditions.
 Key questions
– What is the prevalence of mental distress, anxiety, and depression among persons
affected by leprosy and their family members?
– What is the impact of mental distress, anxiety, and depression on health care and
programmatic outcomes, such as case detection, treatment adherence, self-care and
rehabilitation?
– How can a negative impact on mental wellbeing be mitigated once it has occurred?
4 . UN PRINCIPLES AND GUIDELINES FOR THE ELIMINATION OF
DISCRIMINATION
The UN Human Rights Council adopted Principles and Guidelines for the Elimination of
Discrimination against Persons Affected by Leprosy and Their Family Members in 2010.
However, very few studies have addressed the implementation of this important document.
Studies are needed to assess the (local) implementation and impact of these principles and
guidelines, and interventions should be developed to improve this practice.
 Key questions
– What is the status of the implementation of the UN Principles and Guidelines for the
Elimination of Discrimination Against Persons Affected by Leprosy and Their Family
Members?
– What is the impact of these principles and guidelines?
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